Protocol  
Title of  trial: 
A Randomised, Double -blind, Placebo -controlled, Response -adaptive Dose - 
finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses 
of FE 201836, with Desmopressin Orally Disintegrating Tablet as a 
Benchmark, During [ADDRESS_1049122] n umber : 
[STUDY_ID_REMOVED]  
Sponsor trial c ode: 
000233   
Date:  
05 Jul 2018  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 1 of 155 
 FE 201836  Trial C ode: [ADDRESS_1049123] Number:  2016-003851 -31 
IND Number:  [ADDRESS_1049124]:  FE 201836  
Indication:  Nocturia  due to Nocturnal Polyuria  
Phase:  2 
Name [CONTACT_2259]:  Ferring Pharmaceuticals A/S  
Global Clinical R&D  
Kay Fiskers Plads 11  
2300 Copenhagen S, Denmark  
Tel: [PHONE_15971]  
Version:  5.0 (consolidated protocol; changes introduced with global 
amendment s #01, #02, and #03  implemented ) 
GCP Statement:  This trial will be performed in compliance with GCP.  
The information in this document is confidential and is proprietary to Ferring Pharmaceuticals A/S or another company 
within the Ferring Group. It is understood that information in this document shall not be disclosed to any third party, in 
any form, without prior written consent of an authorised officer of Ferring Pharmaceuticals A/ S or another company 
within the Ferring Group.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 2 of 155 
 FE 201836  Trial C ode: [ADDRESS_1049125] visit : Q3 [ADDRESS_1049126] visit : Q3 2019 CLINICAL PHASE  
Phase 2  
BACKGROUND AND SCIENTIFIC JUSTIFICATION FOR CONDUCTING THE TRIAL  
Nocturia is defined by [CONTACT_67285] (ICS) as waking from sleep (during the 
night) at least once to urinate. This may occur when there is an excessive urine production during 
the night (noc turnal polyuria [NP]). The anti diuretic hormone arginine vasopressin (AVP) plays a 
key role in the control of urine production during the night. Desmopressin,  a synthetic analogue of 
AVP  developed by [CONTACT_480222] , is approved and used for the treatment of nocturia due 
to NP in more than 80  countries, including Canada and European countries. However, 
desmopressin has not yet been approved for this indication in the [LOCATION_003] .  
Low doses of desmopressin (25 ¬µg for women and 50 ¬µg for men) are approved to date in Canada, 
Australia and European countries under the trade name [CONTACT_765444] (desmopressin Orally 
Disintegrating Tablet [ODT]). These gender specific minimum effective low doses are approved for 
use in all adult ages an d are indicated for treatment of nocturia due to NP in adults, who awaken 
two or more times each night to void. The global cumulative patient exposure of NOCDURNA by 
[CONTACT_124702]-2016 is 1,389 patient years based on a dose of 25  Œºg for women and 50  Œºg for men (wome n: 
779 patient years; men: 610 patient years). Analysis of the combined data from three trials of 
low-dose desmopressin ODT, comprising >1400 patients with nocturia, shows that desmopressin 
dose, patient age, baseline serum sodium levels, and kidney functi on according to estimated 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 3 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  glomerular filtration rate clearance were significant risk factors for hyponatraemia in both sexes.  
Ferring Pharmceuticals is currently developi[INVESTIGATOR_765343]  201836, another  synthetic analogue of AVP and 
a potent and highly selective shor t-acting vasopressin -2 (V 2)-receptor agonist with an antidiuretic 
action profile suitable for treating nocturia due to NP in adults. FE [ADDRESS_1049127] should provide an antidiure tic 
duration of action not exceeding 6 -8 hours i.e., corresponding to the night -time sleep period when 
drinking does not occur or is limited to a minimum  (to satisfy thirst).  The oral half-life should be 
shorter than that of desmopressin and the key route of metabolism non -renal, since the clinical 
promise of a short -acting V 2-receptor agonist is based on an improved safety profile without a 
prolonged duration of action leading to hyponatraemia. A shorter and more predictable duration of 
antidiuretic action  would minimise the risk of hyponatraemia and may reduce the need for serum 
sodium monitoring.  
In the present clinical trial, 6 doses of FE  201836 (50-500 ¬µg) will be evaluated for estimation of 
the dose -response curve, where the response is the change in the number of nocturnal voids. The 
choice of FE  [ADDRESS_1049128] of FE  201836 in 
healthy subjects and by [CONTACT_765371].  
In phase 1 trial 000195  in young healthy men and women oral doses of FE  201836 up to 4800  ¬µg 
(i.e., 9.6  times higher than the suggested maximum dose in the present phase 2 trial) were 
administered and found to be safe and well tolerated. The exposure after  intravenous infusion of 
0.[ADDRESS_1049129].  
The present trial is powered for detecting differences in treatment effec ts between FE  201836 and 
placebo. Desmopressin is included as benchmark treatment . There is no prospectively planned 
power for conclusive inference  with regards to differences between desmopressin and placebo (or 
FE 201836).  
In order to select trial subjec ts with nocturia primarily due to the underlying condition of NP driven 
with increased Free Water Clearance (FWC), who will benefit the most from treatment with an 
antidiuretic agent, a 1 -week active run -in period followed by a 1 -week washout period  (refer red to 
as the ‚Äòenrichment period‚Äô)  will be applied to ensure that drug -responders (defined as a reduction of 
nocturnal diuresis [mL/min]of 20% or more) are identified. The ‚â•20% dec rease in the nocturnal 
diuresis rate  has been established as a relevant mark er of antidiurectic responsivene ss in previous 
nocturia trials  with an active run -in. The majority of fluid output occurs via the urine, 
approximately 1 ,500 mL/day, therefore there is no evidence in adult nocturia patients that the 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 4 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  relative change over the  time in nocturnal diuresis rate ( mL/min  normalised to time in bed) should 
be adjusted for body weight and or/body surface area which are both assumed to be constant over a 
short period of just [ADDRESS_1049130] data found that reducing 
Nocturnal Urine V olume (NUV) and increasing  the duration of antidiuretic action of a V 2-receptor 
agonist (desmopressin) was a significant predictor for subsequent decrease from baseline in the 
number of nocturnal voids.  
The underlying pathophysiologic mechanism of NP can be driven by [CONTACT_765372] d FWC, which 
based on mode of action will be responsive to antidiuretic treatment, or by [CONTACT_765373], which differs s ubstantially in mode of action and is governed by [CONTACT_765374] (ANP) which again is directly and indirectly influenced by [CONTACT_765375] -Angiotensin -
Aldosterone System (RAAS).  
The aim of the active run -in is (after excluding all other medical causes of NP) to identify subjects 
with increased FWC which is  responsive to V 2-receptor agonism. In addition, safety will be 
assessed in this period with spe cial emphasis on hyponatraemia.  
OBJECTIVES  
Primary Objective  
‚Ä¢ To establish the dose -response of FE [ADDRESS_1049131] to the number of nocturnal voids 
in subjects with nocturia due to NP.  
Secondary Objectives  
‚Ä¢ To evaluate responder rates with regards to changes in  number of nocturnal voids.  
‚Ä¢ To psychometrically validate the Nocturia Impact Diary¬© (NI Diary).  
‚Ä¢ To evaluate the patient benefit of FE 201836 based on the NI Diary data.  
‚Ä¢ To evaluate the clinical benefit of FE 201836 based on reduction in nocturnal voiding.  
‚Ä¢ To evaluate FE [ADDRESS_1049132] Undisturbed 
Sleep Period ( FUSP) and sleep related Patient Reported  Outcomes (PROs).  
‚Ä¢ To evaluate the pharmacodynamic (PD) effect of FE [ADDRESS_1049133] to  nocturnal 
diuresis rate and NP.  
Safety Objective  
‚Ä¢ To evaluate the safety profile of FE  201836.  
Exploratory Objectives  
‚Ä¢ To explore the biomarker c opeptin, an AVP surrogate, to identify low nocturnal vasopressin 
levels in plasma.  
‚Ä¢ To explore the dose -response of FE [ADDRESS_1049134] to total sleep time.  
‚Ä¢ To explore the association between total sleep time and FUSP.  
‚Ä¢ To explore the effect of FE [ADDRESS_1049135] to Nocturnal Polyuria index ( NPi). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 5 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ To benchmark the efficacy of FE 201836 in relation to desmopressin.  
ENDPOINTS  
Primary Endpoint  
‚Ä¢ Change from b aseline in number of nocturnal voids during 12  weeks of treatment.  
Secondary Endpoints  
‚Ä¢ Change from b aseline in number of nocturnal voids at Weeks 1, 4, 8 and 12.  
‚Ä¢ Responder rate defined as 50% reduction in nocturnal voids from baseline at Weeks 1, 4, 8 
and 12 and during 12  weeks of treatment.  
‚Ä¢ Change from b aseline in NI Diary Total Score at Weeks 1, 4, 8 and 12 and d uring 12  weeks 
of treatment.  
‚Ä¢ Percentage of nights during the treatment period with at most one nocturnal void.  
‚Ä¢ Percentage of nights during the treatment period with complete response, i.e. , with no 
nocturnal voids.  
‚Ä¢ Change from b aseline in NI Diary Overall Impact Score at Weeks 1, 4, 8 and 12 and during 
12 weeks of treatment.  
‚Ä¢ Patient Global Impression of Improvement (PGI -I) urinary symptoms scores at Weeks 1, 4, 
8 and 12.  
‚Ä¢ Change from b aseline in Patient Global Impression of Severity (PGI -S) scores at Weeks  1, 
4, 8 and 12.  
‚Ä¢ Change from b aseline in Bother as measured by [CONTACT_765376] 5 -point Likert Bother scale at 
Weeks  1, 4, 8 and 12.  
‚Ä¢ Change from b aseline in Insomnia Severity Index (ISI) at Weeks 4, 8 and 12.  
‚Ä¢ Change from b aseline in FUSP at 1, 4, 8 and 12 weeks of tr eatment and during 12  weeks.  
‚Ä¢ Change from b aseline in nocturnal diuresis rate (hourly) profiles at Week  1 and Week  12. 
‚Ä¢ Change from b aseline in NUV  at Week 1 and Week  12. 
Safety Endpoints  
‚Ä¢ Incidence and severity of adverse events.  
‚Ä¢ Incidence of hyponatraemia as measured by [CONTACT_765377].  
‚Ä¢ Change from baseline  in mean 24 -hour urine volume at Week 1 and Week  12. 
‚Ä¢ Clinically significant changes in vital signs and laboratory values.  
Exploratory Endpoints  
‚Ä¢ Responder rates defined as 33%, 60%, 70%, 80%, 90% and 100% reduction  from baseline 
in number of nocturnal voids at Weeks 1, 4, 8 and 12.  
‚Ä¢ Responder rates defined as 1, 2, and 3 voids reduction  from baseline in number of nocturnal 
voids at Weeks 1, 4, 8 and 12.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 6 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ The correlation of c opeptin  levels to NPi [CONTACT_293778]  2. 
‚Ä¢ Change from b aseline in c opeptin levels at Week  12. 
‚Ä¢ Change from b aseline in total sleep time per night at Weeks 1, 4, 8 and 12 and during 
12 weeks of treatment.  
‚Ä¢ Correlation between change from b aseline in tot al sleep time and FU SP at Weeks  1, 4, 8 
and 12. 
‚Ä¢ Change from b aseline in NP i at Week 1 and Week 12 . 
METHODOLOGY  
This is a randomised, double -blind, placebo -controlled, response -adaptive, dose -finding trial 
investigating the efficacy, safety and tolerability of 6 different oral doses ( 50-500 ¬µg) of 
FE 201836, with desmopressin as a benchmark, during [ADDRESS_1049136] of a 2 -week screening/lifestyle changes 
period where no Investigational Medicinal Product ( IMP) will be given, an enrichment period 
consisting of a 1-week single -blind (to subjects) active run -in period and a [ADDRESS_1049137] . During th e active run -in 
period the trial subjects will receive 500  ¬µg FE 201836 and placebo to assess safety and establish 
that subjects who respond to treatment with FE  201836 are included in the trial (i.e., an enrichment 
design).  
The 12 -week double -blind random ised treatment period of the trial will follow  a response -adaptive 
Bayesian top -down design. Initially subjects will be randomised to: placebo, 500  ¬µg FE  201836 or 
desmopressin (for benchmarking only). When approximately [ADDRESS_1049138] been randomised t o 
the trial, an interim analysis will be conducted  to investigate the efficacy of 500  ¬µg FE  201836. If 
500 ¬µg FE  201836 is not sufficiently efficacious compared to placebo the trial will be stopped for 
futility. If 500  ¬µg FE  201836 is efficacious additiona l doses of FE  201836 (doses 50 -350 ¬µg) will 
be opened up for randomisation of new sub jects in order to identify the Minimum Effective Dose 
(MED) and near maximal Effective D ose (ED 85). The ED [ADDRESS_1049139] 
85% of the effect of  the maximum dose (500  ¬µg). After the first interim analysis, subsequent 
interim analyses will take place every [ADDRESS_1049140] interim analysis eligible subjects will be randomised to one of 8 treatment groups  
(Table S -1). Each subject will be instructed to take the IMP every night at bedtime with the 
intention to sleep. In order to keep the treatment blinded each subject will receive two medications 
throughout th e trial; an oral solution and an Orally Disintegrating Tablet (ODT), i.e., a double -
dummy design will be applied because desmopressin is available in an ODT formulation and 
FE 201836 is an oral solution.  
Subjects will be asked to follow lifestyle changes ( e.g., limiting fluid intake) throughout the entire 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 7 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  duration of the trial. In addition, subjects will be asked to complete electronic diary (e -Diary) 
assessments  and Patient Reported Outcome (PRO) questionnaires  before and after randomisation. 
One objectiv e of the present trial is to further validate the NI Diary. Therefore, a sample of subjects 
(from trial sites in the US A) who have completed the trial will be invited to participate in an exit 
interview within 14 days of attending the end -of-trial visit (V isit 8), to record the subjects‚Äô 
perception of what constitutes a meaningful change in the NI Diary Total Score . 
Safety, including serum sodium levels, adverse events and clinically significant changes in vital 
signs and laboratory values will be monitored  throughout the trial and reviewed on an ongoing 
basis by a Safety Review Committee (SRC) . 
Furthermore, the risk for subjec ts developi[INVESTIGATOR_765344] a serum sodium 
monitoring plan , including a 1-week active run -in period to identify subjects at increased risk for 
developi[INVESTIGATOR_765345] . If the incidence of serum sodium levels 
<130  mmol/L is statistically significantly >10% during the active run -in, the Data Monitoring 
Committee (DMC) will be notified and  further action will be discussed, e.g., the DMC may 
recommend that the highest dose of FE  201836 ma y be replaced by a lower dose. T he trial is 
designed so the dose may be lowered from 500  ¬µg to 3 50 ¬µg, if recommended by [CONTACT_1363] . 
NUMBER OF SUBJECTS  
A maximum of 300 subjects (males and females) will be  randomised into the trial.  At least 50% of 
subjects should be randomised at trial sites in the [LOCATION_003].  
CRITERIA FOR INCLUSION / EXCLUSION  
Inclusion Criteria  
Each subject must meet the following inclusion criteria between Visit 1 (screening) throu gh Visit  4 
(randomisation) : 
1. Written informed consent prior to performance of any trial -related activity  
2. Adults ‚â•18 years of age (at the time of written consent)  
3. Female subjects of child-bearing potential must be wi lling and able  to use adequate 
contraception throughout the trial. Documentation of an acceptable  effective method  of 
contraception  must be available . All pre - and perimenopausal subjects have to perform 
pregnancy tests. Amenorrhea of more than [ADDRESS_1049141] reported nocturia symptoms during the 6 months prior to Visit  1 
5. ‚â•2 nocturnal voids (an average over 3 days) as documented in the [ADDRESS_1049142] be ‚â•200 mL (at least 1 void ‚â•200 mL) as documented in 
the 3 -day e -Diary prior to Visit 2  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 8 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  7. Nocturnal polyuria, defined as NPi >33%, a ratio of NUV in excess of 33% of total daily (24 -
hour) urine volume as documented in the 3 -day e -Diary prior to Visit  2 
8. b 
9. ‚â•20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit  2) as 
documented in the [ADDRESS_1049143] ‚â•2 nocturnal voids (an 
average over 3 days) as documented in the [ADDRESS_1049144] meeting one or more of the following exclu sion criteria between Visit 1 (screening) 
through Visit 4 (randomisation) will be considered as a screening failure : 
1. Current diagnosis of Obstructive Sleep Apnoea (OSA)  
2. Restless Legs Syndrome (RLS)  
3. Suspi[INVESTIGATOR_765346] O utlet Obstruction (BOO) or urine flow <5 mL/s , as confirmed by 
[CONTACT_765378] 2   
4. Urinary incontinence defined as an average of >1 epi[INVESTIGATOR_1865]/day in the 3 -day e-Diary prior to 
Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not 
necessarily exclusionary)  
5. c 
6. Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation 
within the past 6 months prior to Visit  1. Includ ing e.g., transurethral resection for BOO or 
Benign Prostatic Hyperplasia (BPH ), hysterectomy or female incontinence procedures  
7. Genito -urinary tract pathology that can in the investigator‚Äôs opi[INVESTIGATOR_765347] e.g., s ymptomatic or recurrent urinary tract infections, interstitial 
cystitis, bladder -related pain, chronic pelvic pain syndrome, or stone in the bladder or  urethra 
causing symptoms  
8. A history of cancer with the last date of disease activity/prescence of maligna ncy within the last 
12 months  prior to Visit  1, except for adequately treated basal cell carcinoma of the skin  
9. History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple 
Sclerosis, Parkinson‚Äôs, spi[INVESTIGATOR_1828], spi [INVESTIGATOR_113163])  
10. Habitual (fluid intake >3L per day) or psychogenic polydipsia  
11. Uncontrolled hypertension , as judged by [CONTACT_093]  
                                              
b Original inclusion criterion omitted as per Clinical Trial Protocol Amendment 02 (applicable for all trial sites).  
c Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 9 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  12. a 
13. Uncontrolled diabetes mellitus , as judged by [CONTACT_093]  
14. Central or nephrogenic diabetes insipi[INVESTIGATOR_27562]  
15. Known history of Syn drome of Inappropriate Antidiuretic Hormone ( SIADH) secretion  
16. History of g astric retention  
17. Suspi[INVESTIGATOR_765348], ([LOCATION_001] Heart Association [NYHA] class 
II, III, IV)  
18. Hyponatraemia:  
‚Ä¢ Serum sodium level <135 mmol/L at Visit  1(re-tested, with results available within 7  days)  
‚Ä¢ Serum sodium level <130 mmol/L at Visit  3 (re-tested, with results available within 7  days)  
19. Hepatic and/or biliary diseases:  
‚Ä¢ Child -Pugh Class A, B, or C  
or 
‚Ä¢ Aspartate aminotransferase and/or al anine aminotransferase levels >3 x the upper limit of 
normal range  as well as total bilirubin level >2x the upper limit of normal range  
20. Known history of hypersensitivity to desmopressin ODT  
21. Pregnancy, breastfeeding, or a planning to become pregnant during the per iod of the trial  
22. Known alcohol or substance abuse  
23. Work or lifestyle that may interfere with regular night -time sleep e.g. , shift workers  
24. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, 
or language barrie r that, in the judgment of the i nvestigator, would impair participation in the 
trial 
25. d 
26. Previous participation in a nocturia, B enign  Prostatic Obstruction (BPO), or OAB clinical trial 
within the past [ADDRESS_1049145] degree family member, significant other or relative  residing 
with one of the above persons involved directly or indirectly with the trial  
                                              
a Original exclusion criterion omitted as per Clinical Trial Protocol Amendment 01 (applicable for all trial sites).  
d Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all t rial sites).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 10 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  28. Use of any restricted therapy not in accordance with the protoco l 
29. Use of any prohibited therapy listed below:  
‚Ä¢ Current or former (within 3 months prior to screening) trea tment with any other IMP  
‚Ä¢ Unstable electrostimulation or behavioural bladder training program less than 3  months 
prior to screening (stable electrostimulation or behavioural bladder training program started 
at least 3 months before screening are acceptable)   
‚Ä¢ Thiazide diuretics  
‚Ä¢ Antiarrhythmic agents  
‚Ä¢ V2-receptor antagonists/agonists  (e.g., vaptans/desmopressin, vasopressin)  
‚Ä¢ Loperamide  
‚Ä¢ Botulinum toxin (cosmetic non -urological use is acceptable)  
‚Ä¢ Valproate  
INVESTIGATIONAL MEDICINAL PRODUCTS  
In order to  maintain the treatment blinding each subject will receive 2 medications ( a 
double -dummy  design), an oral solution and an ODT  formulation, during every treatment period  of 
the trial, as outlined in Table S -1. 
Table S -[ADDRESS_1049146] Interim Analysis    
500 ¬µg FE 201836  500 ¬µg FE 201836  oral solution  Placebo ODT  
Desmopressin  Desmopressin ODT  (25¬µg for 
females and  50 ¬µg for males)  Placebo oral solution  
Placebo  - Placebo oral solution and Placebo ODT  
After First Interim  Analysis    
50 ¬µg FE 201836  50 ¬µg FE 201836 oral solution  Placebo ODT  
100 ¬µg FE 201836  100 ¬µg FE 201836 oral solution  Placebo ODT  
150 ¬µg FE 201836  150 ¬µg FE 201836 oral solution  Placebo ODT  
250 ¬µg FE 201836  250 ¬µg FE 201836 oral solution  Placebo ODT  
350 ¬µg FE 201836  350 ¬µg FE 201836 oral solution  Placebo ODT  
500 ¬µg FE 201836  500 ¬µg FE 201836 oral solution  Placebo ODT  
Desmopressin  Desmopressin ODT  (25¬µg for 
females and 50 ¬µg for males)  Placebo oral solution  
Placebo - Placebo oral solution and Placebo ODT  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 11 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049147] 125  subjects will be treated daily with placebo, 
500 ¬µg FE 201836 or desmopressin (25 ¬µg for females and 50  ¬µg for males ) for up to [ADDRESS_1049148] been randomised an interim analysis will be conducted  and a 
decision taken on whether to continue the trial as planned  or stop the trial for futility.  
If the decision is to continue the trial as planned,  subjects may be randomised to one of 8  treatment 
groups  for 12  weeks : placebo, 50 ¬µg FE 201836, 100  ¬µg FE 201836, 150  ¬µg FE  201836, 2 50 ¬µg FE 
201836, 350  ¬µg FE 201836, 500 ¬µg  FE 201836 , or desmopressin (25  ¬µg for females and 50 ¬µg for 
males) . 
STATISTICAL METHODS  
Primary Analysis Model used in  the Response -adaptive Trial Design  
The primary an alysis is based on a time -course hierarchical longitudinal model, i.e.,  
ùëåùë°,ùëñ=ùëíùõæùë°(ùúáùëë,ùëñ+ùõøùëñ)+ ùúÄùë° 
where Y t,i is the change from baseline in number of nocturnal voids at visit t for subject i, d is the 
dose, ùëíùõæùë° the fraction of the effect at Visit t (Week 1, Week  4 or Week 8) as compared to the Month 
3 visit ( ùõæt=0 at Month 3), Œ¥ i the random subject effect and Œµ t the independent N(0, ùúÜùë°2) distributed 
error term. The dose -response for subject  ùëñ, ùúáùëë,ùëñ, is adjusted for the number of baseline voids ( ùë•0,ùëñ) 
and modelled using the sigmoidal E -max model, i.e.,  
ùúáùëë,ùëñ=ùõΩùë•0,ùëñ+ùõº1+(ùõº2‚àíùõº1) ùëëùõº4
ùëëùõº4+ùõº3ùõº4=ùõΩùë•0,ùëñ+ùúáùëë  
Inference will be based on a Bayesian analysis using sufficiently non -informative priors on 
respective parameters. The trial will be considered successful if the maximum dose has a greater 
than 97.5% posterior probability of being better than placebo, i.e. , if Pr( ŒºMAX < Œº Plb) > 97.5%.  
Response -adaptive Decision Rules  
The double -blind treatment period is based on a response -adaptive Bayesian top -down design. 
After an initial [ADDRESS_1049149] been randomised to placebo, 500 ¬µg FE 201836  (the highest dose) 
or desmopressin in a 2:2:[ADDRESS_1049150] to stop for futility if the Pr ( ŒºMAX 
‚Äì ŒºPlb < -0.3) <10%, where Pr (.)  denotes posterior probability (under the assumed mon otonic dose -
response relation, i.e. smaller doses will be less e ffective).  
If not stopped for futility, all treatment arms will be opened up for randomisation, subjects can be 
randomised to placebo, desmopressin or to any FE 201836 dose (50 -500 ¬µg) in a 2:1:7 ratio. When 
allocated to a FE  201836 dose (7/10), unrestrict ed randomisation will be used to allocate a subject 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 12 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  to a specific FE  201836 dose using an allocation probability that is the average of I(dose is MED) 
and I(dose is ED 85), where I(target)  is the probability that ‚Äúdose is target‚Äù scaled by [CONTACT_765379]. The MED is the lowest dose that has at least a ‚àÜ=0.[ADDRESS_1049151] 
85% of the effect of the  maximum dose ( 500 ¬µg).  
After the first interim analysis, subsequent interims will take place every [ADDRESS_1049152] if Pr ( ŒºMAX ‚Äì ŒºPlb < -0.3) < 5.  
Operating Character istics  
Under the assumptions (based on previous  desmopressin trials and feasibility) that:  
‚Ä¢ Response fractions of 0.8142, 0. 9328 and 0.9874 at Weeks 1, 4 and 8, respectively , as 
compared to the averaged dose -response at Week 12  
‚Ä¢ Varian ce fractions of 0.8481 , 0.8329 and 0.8900 at Weeks 1, 4 and 8, respectively, as 
compared to the averaged dose -response at Week 12  
‚Ä¢ A constant drop -out rate of 15% during the randomised treatment period  
‚Ä¢ A between to total variance (œÉ2) ratio of 0.90 and a true underlying œÉ of 0.9 5 
‚Ä¢ During the initial 17 weeks  the recruitment rate will increase line arly from 0  to 8.2 subjec ts 
per week  
‚Ä¢ After [ADDRESS_1049153] been initiated, the recruitment rate is assumed to 
remain constant at 8.2  subjects per week  
and  
‚Ä¢ Considering six dose-response scenarios for the mean change from baseline to a large extent 
is characterised by [CONTACT_765380] ( 500 ¬µg FE  201836 )  
Given these assumptions the operating characteristics presented in Table S -2 apply:  
Table S -2 Operating Characterisitics  
Dose -Response 
Scenario  Maximum 
response 
(ùõº2) ED 50 
(ùõº3) Average 
Number of 
Subjects  Futility 
Stoppi[INVESTIGATOR_765349] 
(Total  
Success)  
Null 0 0 ¬µg 200 75.8% 97.0% 3.0% 
I -0.3 150 ¬µg  277 15.7% 47.9% 52.1% 
II -0.4 200 ¬µg  288 7.9% 25.1% 74.9% 
III -0.5 200 ¬µg  296 2.8% 9.6% 90.4% 
IV -0.5 350 ¬µg  295 3.4% 15.4% 84.6% 
V -0.6 300 ¬µg  298 1.4% 2.7% 97.3% 
 
For each dose -response scenario, 1 ,000 trials were simulated in order to estimate the operating 
characteristics presented in Table S -2. Assuming a maximum re duction versus placebo of 0.5  voids 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 13 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  the power (probability o f success ) reaches approximately 85 to 90%, while the probability of 
making a false positive conclusion is 3.0%. 
Randomisation if the Maximum  Dose  is Lowered  
The trial has been designed with the option to decrease the maximum  dose of FE  [ADDRESS_1049154] interim analysis 
(when the  first 125 subjects are randomised) the remaining subjects will be randomised to the 
following treatment groups: placebo, desmopressin (25 ¬µg for females and 50 ¬µg for males) or 
[ADDRESS_1049155] interim analysis  the dose -response adaptive randomisation will 
allocate subjects to the remaining open doses, i.e., one of 7 treatment groups: placebo, 50  ¬µg FE 
201836, 100  ¬µg FE 201836, 150  ¬µg FE 201836, 250  ¬µg FE 201836, 350  ¬µg FE 201836, or 
desmopressin (25 ¬µg fo r females and 50 ¬µg for males).  
The dose -response model will be fitted across all doses, i.e., 0 -500 ¬µg, but inference will be made 
only on the doses th at remain open to randomisation  e.g., 0 -350 ¬µg. That is, the MED and ED 85 
doses and the inferences with regards to proof -of-concept and fu tility are limited to the dose range 
(i.e, with a maximum  dose of  350 ¬µg FE  201836).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 14 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049156] OF ABBR EVIATIONS AND DEFINITION OF TERMS  ................................ ...................... 19 
1 INTRODUCTION  ................................ ................................ ................................ ............. 22 
1.1 Background ................................ ................................ ................................ ............. 22 
1.2 Scientific Justification for Conducting the Trial  ................................ ............................ 24 
1.3 Benefit / Risk Aspects ................................ ................................ ............................... 24 
2 TRIAL OBJECTIVES AND ENDPOINTS  ................................ ................................ .......... 26 
2.1 Objectives ................................ ................................ ................................ ............... 26 
2.2 Endpoints  ................................ ................................ ................................ ............... 26 
3 INVESTIGATIONAL PLAN ................................ ................................ .............................. 28 
3.1 Overall Trial Design  ................................ ................................ ................................ .28 
3.1.1  Trial Design Diagrams ................................ ................................ ................... 28 
3.1.2  Overall Design and Control Methods  ................................ ............................... 31 
3.1.3  Trial Schedule  ................................ ................................ .............................. 32 
3.2 Planned Number of Trial Sites and Subjects  ................................ ................................ .32 
3.3 Interim Analyses  ................................ ................................ ................................ ......32 
3.4 Safety Review and Data Monitoring Committees  ................................ .......................... 32 
3.5 Discussion of Overall Trial Design and Choice of Control Groups  ................................ ...33 
3.5.1  Trial Design  ................................ ................................ ................................ .33 
3.5.2  Selection of Endpoints  ................................ ................................ ................... 34 
4 SELECTION OF TRIAL POPULATION  ................................ ................................ ........... 36 
4.1 Trial Population  ................................ ................................ ................................ ....... 36 
4.1.1  Inclusion Criteria  ................................ ................................ .......................... 36 
4.1.2  Exclusion Criteria  ................................ ................................ ......................... 37 
4.2 Method of Assigning Subjects to Treatment Groups  ................................ ...................... 39 
4.2.1  Recruitment  ................................ ................................ ................................ .39 
4.2.2  Randomisation  ................................ ................................ ............................. 40 
[IP_ADDRESS]  Randomisation if Maximum Dose is Lowered  ................................ .....[ADDRESS_1049157] yle Changes and Other Restrictions  ................................ ......................... 43 
4.3.4  Contraception ................................ ................................ ............................... 43 
4.4 With drawal Criteria  ................................ ................................ ................................ ..44 
5 TREATMENTS ................................ ................................ ................................ ................. 45 
5.1 Treatments Administered  ................................ ................................ .......................... 45 
5.2 Characteristics and Source of Supply  ................................ ................................ .......... 46 
5.2.1  Investigational Medicinal Products  ................................ ................................ ..46 
5.3 Packaging and Labelling  ................................ ................................ ........................... 46 
5.4 Conditions for Storage and Use  ................................ ................................ .................. 46 
5.5 Blinding/Unblinding ................................ ................................ ................................ .47 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 15 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049158] Treatment ................................ ...................... 47 
5.6 Treatment Compliance  ................................ ................................ .............................. 48 
5.6.1  Dispensing and Accountability ................................ ................................ ........ 48 
5.6.2  Assessment of Compliance ................................ ................................ ............. 48 
5.7 Return and Destruction of Investigational Medicinal Products ................................ ......... 48 
6 TRIAL PROCEDURES  ................................ ................................ ................................ .....49 
6.1 Trial Flow Chart  ................................ ................................ ................................ ......49 
6.2 Visit 1 Screening ................................ ................................ ................................ ......51 
6.3 Visit 2 Active Run -in Period  ................................ ................................ ...................... 52 
6.4 Visit 3 Washout Period  ................................ ................................ ............................. 52 
6.5 Visit 4 ................................ ................................ ................................ .................... 53 
6.6 Visit 5 to V isit 7 ................................ ................................ ................................ ......53 
6.7 Visit 8 ‚Äì End-of-Trial Visit  ................................ ................................ ........................ 54 
6.8 Unscheduled Visits ................................ ................................ ................................ ...54 
7 TRIAL ASSESSMENTS  ................................ ................................ ................................ ....56 
7.1 Asse ssments Related to Endpoints  ................................ ................................ .............. 56 
7.1.1  e-Diary ................................ ................................ ................................ ........ 56 
[IP_ADDRESS]  3-Day Voiding Diary ................................ ................................ ....... 56 
[IP_ADDRESS]  Nocturia Impact Diary  ................................ ................................ .....58 
[IP_ADDRESS]  Patient Reported Outcomes  ................................ .............................. 59 
[IP_ADDRESS].1  Patient Global Impression of Severity and Patient 
Global Impression of Disease Improvement  ...................... 59 
[IP_ADDRESS].2  Insomnia Severity Index ................................ ................. 59 
[IP_ADDRESS].3  Bother  ................................ ................................ ......... 60 
7.1.2  Adverse Events  ................................ ................................ ............................ 61 
7.1.3  Clinical Laboratory Variables  ................................ ................................ ......... 61 
[IP_ADDRESS]  Serum Sodium ................................ ................................ ................ 62 
[IP_ADDRESS]  von Willebrand Factor and Factor VIII  ................................ ............... 63 
[IP_ADDRESS]  Copeptin ................................ ................................ ........................ [ADDRESS_1049159]  ................................ ................................ ............................. 65 
7.2.7  Electrocardiogram ................................ ................................ ......................... 65 
7.3 Handling of Biological Samples  ................................ ................................ ................. 65 
8 ADVERSE EVENTS ................................ ................................ ................................ .......... 66 
8.1 Adverse Event Definition  ................................ ................................ .......................... 66 
8.2 Collection and Recording of Adverse Events  ................................ ................................ 66 
8.2.1  Collection of Adverse Events ................................ ................................ .......... 66 
8.2.2  Recording of Adverse Events ................................ ................................ .......... 66 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 16 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049160] Visit in the Trial  ......... 72 
9 STATISTICAL METHODS  ................................ ................................ ............................... 73 
9.1 Operating Characteristics  ................................ ................................ .......................... 73 
9.2 Protocol Deviations  ................................ ................................ ................................ ..75 
9.3 Analysis Sets  ................................ ................................ ................................ ........... 76 
9.3.1  Intention -to-Treat Analysis Set for the Enrichment (ITT -ENR) Period  .................. 76 
9.3.2  Safety Analysis Set for the Enrichment Period ................................ ................... 76 
9.3.3  Intention -to-Treat ( ITT) Analysis Set for the Randomised Treatment Period  .......... 76 
9.3.4  Full Analysis Set (FAS)  ................................ ................................ ................. 76 
9.3.5  Per Protocol (PP) Analysis Set  ................................ ................................ ........ [ADDRESS_1049161] Disposition  ................................ ................................ ................................ ..76 
9.5 Enrichment Period Assessments and Analysis Sets  ................................ ........................ 77 
9.6 Trial Population  ................................ ................................ ................................ ....... 77 
9.6.1  Medical History, Concomitant Medication and Other Safety Evaluations  .............. 77 
9.7 Endpoint Assessments  ................................ ................................ .............................. 77 
9.7.1  General Considerations  ................................ ................................ .................. 77 
9.7.2  Primary Analysis  ................................ ................................ .......................... 78 
[IP_ADDRESS]  Statistical Dose -Response Model  ................................ ...................... 78 
[IP_ADDRESS]  Overall Trial Outcome  ................................ ................................ .....80 
[IP_ADDRESS]  Dose -Response ................................ ................................ ............... 80 
[IP_ADDRESS]  Sensitivity Analyses  ................................ ................................ ........ 80 
[IP_ADDRESS]  Descriptive Analysis  ................................ ................................ ....... 80 
9.7.3  Secondary and Explorative Analyses  ................................ ............................... 81 
[IP_ADDRESS]  Therapeutic Window  ................................ ................................ ....... [ADDRESS_1049162]: Hyponatraemia Epi[INVESTIGATOR_1841]  .............................. 84 
[IP_ADDRESS]  Hyponatraemia during the Randomised Treatment Period  ..................... 85 
9.10.4  Safety Laboratory Variables  ................................ ................................ ........... 85 
9.11  Interim Analyses  ................................ ................................ ................................ ......85 
9.11.1  Serum Sodium Monitoring during the Active Run -In Period ................................ 86 
9.11.2  Interim Efficacy Analyses  ................................ ................................ .............. 87 
10 DATA HANDLING  ................................ ................................ ................................ ........... 89 
10.1  Source Data and Source Documents ................................ ................................ ............ 89 
10.2  Electronic Case Report Form  ................................ ................................ ..................... 90 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 17 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049163] Diary  ................................ ........................... 91 
[IP_ADDRESS]  Psychometric Validation  ................................ ................................ ..91 
[IP_ADDRESS]  Validation through Exit Interviews  ................................ .................... [ADDRESS_1049164] OF THE TRIAL  ................................ ............................... 95 
12.1  Protocol Amendments ................................ ................................ ............................... 95 
12.2  Deviations from the Protocol  ................................ ................................ ..................... 95 
12.3  Premature Trial Termination  ................................ ................................ ...................... 95 
13 REPORTING AND PUBLICATION  ................................ ................................ .................. 96 
13.1  Clinical Trial Report ................................ ................................ ................................ .96 
13.2 Confidentiality and Ownership of Trial Data  ................................ ................................ 96 
13.3  Publications and Public Disclosure  ................................ ................................ ............. 96 
13.3.1  Publication Policy  ................................ ................................ ......................... 96 
13.3.2 Public Disclosure Policy  ................................ ................................ ................ 97 
14 ETHICAL AND REGULATORY ASPECTS ................................ ................................ ....... 98 
14.1  Independent Ethics Committee / Institutional Review Board / Research Ethics Board  ......... [ADDRESS_1049165] ................................ ................................ ......................... 99 
14.7  Compliance Reference Documents  ................................ ................................ ............. 99 
15 LIABILITIES AND INSURANCE  ................................ ................................ ....................  100 
15.1  ICH-GCP Responsibilities  ................................ ................................ .......................  100 
15.2  Liabilities and Insurance  ................................ ................................ .........................  100 
16 ARCHIVING  ................................ ................................ ................................ ..................  101 
16.1  Investigator File ................................ ................................ ................................ ..... 101 
16.2  Trial Master File  ................................ ................................ ................................ .... 101 
17 REFERENCES ................................ ................................ ................................ ................  102 
18 APPENDICES ................................ ................................ ................................ .................  105 
Appendix 1  ................................ ................................ ................................ ......................  105 
Appendix 2  ................................ ................................ ................................ ......................  140 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 18 of 155 
 FE 201836  Trial C ode: [ADDRESS_1049166] ................................ ................................ ................................ ..79 
Table 9-3 Overall Trial Criteria  ................................ ................................ ................................ .80 
Table 9-4 Analysis of Endpoints  ................................ ................................ ................................ 82 
Table 9-5 Tabulations of Adverse Events  ................................ ................................ .................... 84 
Table 9-6 Definition of Hyponatraemic Epi[INVESTIGATOR_765350] ................................ ................................ ................................ ....... 85 
Table 9-7 Examples of Incidence Rates that are Statistically Significantly >10%  ............................... [ADDRESS_1049167] During the
Randomised Treatment Period ................................ ................................ ..................... 30 
Figure 9-1 Dose -Response Scenarios  ................................ ................................ ........................... 73 
Figure 9-2 Interim Analysis Decision Tree (2nd Interim Analysis and Onwards)  ................................ 88 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 19 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049168] Research Organisation  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
e-Diary  Electronic Diary  
ED 85 The near (‚â•85%) m aximal  Effective Dose  
EU European Union  
FACTS  Fixed and Adaptive Clinical Trial Simulator  
FAS Full Analysis Set  
FDA Food and Drug Administration  
FWC  Free Water Clearan ce 
FUSP  First Undisturbed  Sleep Period  
GCP  Good Clinical Practice  
GEE Generalized Estimating Equation  
GMP  Good Manufacturing Practice  
ICF Informed Consent  Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IEC Independent Ethics Committee  
IMP Investigational Medicinal Product  
IRB Institutional Review Board  
ISI Insomnia Severity Index  
ITT Intention -to-Treat  analysis set for the randomised treatment period  
ITT-ENR  Intention -to-Treat analysis set for the enrichment period  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 20 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049169] Diary¬© 
NUV  Nocturnal Urine Volume  
OAB  Overactive Bladder  
ODT  Orally Disintegrating Tablet  
OSA  Obstructive Sleep Apnoea  
PAP Psychometric Analysis Plan  
PD Pharmacodynamic  
PGI-I Patient Global Impression of Improvement  
PGI-S Patient Global Impression of Severity  
PK Pharmacokinetic  
PP Per Protocol  
PRO  Patient Reported Outcome  
RAAS  Renin -Angiotensin -Aldosterone System  
REB Research Ethics Board  
RLS Restless Legs Syndrome  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SIADH  Syndrome of Ina ppropriate Antidiuretic Hormone  
SOC  System Organ Class  
SRC Safety Review Committee  
SSRI  Selective Serotonin Reuptake Inhibitors  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 21 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Definition of Terms  
Hyponatraemia  Hyponatraemia  is categoris ed by [CONTACT_765381]:  
‚Ä¢ Normal lower limit of serum sodium >135 mmol/L  
‚Ä¢ Mild hyponatraemia : serum sodium 134 -130 mmol/L  
‚Ä¢ Moderate* hyponatraemia : serum sodium <130 mmol/L  
‚Ä¢ Severe hyponatraemia : serum sodium <125 mmol/L  
* Moderate hyponatraemia  is equivalent to the term ‚Äòclinically significant 
hyponatraemia ‚Äò (Verbalis,  2013) 
Nocturnal diuresis  The nocturnal diuresis rate  is calculated from the mean of 3 days 
Nocturnal Urine Volume ( NUV) and total time  in bed:  
ùëÅùëúùëêùë°ùë¢ùëüùëõùëéùëô  ùëëùëñùë¢ùëüùëíùë†ùëñùë†  ùëüùëéùë°ùëí  (ùëöùêø/ùëöùëñùëõ )=NUV  (mL)
Total  Time  in Bed (min) 
 
FUSP  First Undisturbed Sleep Period (FUSP) is defined as the time in minutes 
from the time of going to bed to the time of first nocturnal void, or time of  
awakening if no void occurred.  
MED  The lowest dose that has at least a ‚àÜ=0.[ADDRESS_1049170] 85% of the effect of the maximum 
dose.  
NPi [CONTACT_440073] i ndex (NP i) is calculated by [CONTACT_765382] (NUV) by [CONTACT_941] 24 -hour urine volume ( van Kerrebroeck, 
2002; Gormley , 2014). 
In this clinical trial the NPi [CONTACT_108] >33% is used for all ages to define 
presence of Noctur nal P olyuria  (NP) . 
NUV  Nocturnal Urine Volume (NUV) is t he total urine volume from [ADDRESS_1049171] void within 
30 minutes of rising  (in the morning) . 
Enrichment 
period  The enrichment period consists of 1 week active run -in followed by 
1 week washout. The enrichment ensures  that subjects  respond to the drug 
(reduction in nocturna diureis by ‚â•20%  from Visit 2 to Visit 3) and have a 
stable condition of ‚â•2 voids at Visit  2 and Visit 4. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 22 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  1 INTRODUCTION  
1.1 Background  
Nocturia is defined by [CONTACT_67285] (ICS) as waking  from sleep (during the 
night) at least once to urinate. Nocturia is a symptom complex associated with several underlying 
medical and urological causes and pathologies ( van Kerrebroeck, 2002 ; Wein , 2002). It is common 
in the elderly, occurring in up to 50% of men and women older than  75 years ( Bosch,  2010). 
Nocturia is associated with a variety of clinical syndromes and disorders, which may result from 
(van Kerrebroeck, 2002 ): 
‚Ä¢ Disorders that cause frequent low volume vo ids (e.g., Overactive Bladder [ OAB ], Bladder 
Outlet Obstruction [ BOO ], stiffer/less -compliant/functionally -smaller  bladder associated 
with aging)  
or 
‚Ä¢ frequent high volume voids (e.g., Nocturnal Polyuria  [NP] , global polyuria [d iabetes 
insipi[INVESTIGATOR_765351]] ) 
or 
‚Ä¢ a combin ation of both, which is common.  
As described  above , NP is a subset of nocturia  defined as excessive volume of urine produced at 
night. The human body typi[INVESTIGATOR_765352]. People with NP produce larger 
volumes of urine when asleep, causing them to awaken multiple times in the night to void. Thus, 
the diagnosis nocturia may be applied  when there is an excessive urine production during the night . 
Nocturnal polyuria  has been attributed to:  
‚Ä¢ Abnormalities in diurnal variation in vasopressin secretion (a condition also coined  as NP 
syndrome ) (Asplund,  1991) 
‚Ä¢ Abnormalities in the diuresis of solutes (e.g., urea, sodium, potassium)  
‚Ä¢ Night time mobilisation of oedematous fluid in conditions such as congestive heart failure, 
nephrotic sy ndrome, or venous insufficiency  
However, as described abo ve, patients often have more than one symptom  presenting as  nocturia 
(or NP); e.g., high volume of urine at night in combination with low volume bladder (perhaps 
associated with ageing) and BOO . 
Taken together, these facts make the clinical situation compl icated since patients may have NP 
overlaid symptoms associated with frequent, low -volume voids, including OAB and Benign 
Prostatic Hyperplasia (BPH) . 
The anti diuretic hormone arginine vasopressin (AVP) plays a key role in the control of urine 
production during the night. Desmopressin, a synthetic analogue of AVP  developed by [CONTACT_765383] , is approved and used for the treatment of noc turia due to NP in more than 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 23 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  80 countries, including Canada and European countries. However, desmopressin has not yet been 
approved for this indication in the [LOCATION_003] . 
Low doses of desmopressin (25 ¬µg for women and 50 ¬µg for men ) are  approved to date in Canada, 
Australia and Europe an countries  under the trade name [CONTACT_765444]  (desmopr essin Orally 
Disintegrating Tablet [ODT]) . These gender specific minimum effective low doses are approved for 
use in all adult ages and are indicated for treatment of nocturia due to NP in adults, who awaken 
two or more times each night to void. The global  cumulative patient exposure of NOCDURNA by 
[CONTACT_124702]-2016 is 1 ,389 patient years based on a dose of 25  Œºg for women  and 50  Œºg for men  (women: 
779 patient years; men : 610 patient years).  Analysis of the combined data from three trials of 
low-dose desmopressin OD T, comprising >1400 patients with nocturia, shows that desmopressin 
dose, patient age, baseline serum sodium levels, and kidney function according to estimated 
glomerular filtration rate clearance were significant risk factors for hyponatraemia in both sex es 
(Juul, 2016). 
Ferring Pharm aceuticals is currently developi[INVESTIGATOR_765343] 201836, another  synthetic analogue of AVP 
and a potent and highly selective short -acting vasopressin -2 (V 2)-receptor agonist with an 
antidiuretic action profile suitable for treating nocturia due to NP in adults. FE [ADDRESS_1049172] should provide an antidiuretic duration of action not 
exceeding 6 -8 hours i.e., corresponding to the night -time sleep period when drinking does not occur 
or is limi ted to a minimum  (to satisfy thirst  only). The oral half -life should be shorter than that of 
desmopressin and  the key route of metabolism non -renal, since th e clinical promise of a short -
acting V 2-receptor agonist is based on an improved safety profile without a prolonged duration of 
action potentially leading to hyponatraemia. A shorter and more predictable duration of antidiuretic 
action would minimise the r isk of hyponatraemia and may reduce the need for serum sodium 
monitoring.  
In the present clinical trial, 6 doses of FE 201836  (50-500 ¬µg) will be evaluated for estimation of 
the dose -response curve, where the response is the change in the number of nocturnal voids. The 
selection  of FE [ADDRESS_1049173] of 
FE 201836 in healthy subjects and by [CONTACT_765384].  In a phase 1 trial (000195 ) in young healthy  men and women , oral doses of 
FE [ADDRESS_1049174].  
The present trial is powered for detecting differences in treatment effects between FE  201836 and 
placebo.  Desmopressin  is inc luded as benchmark treatment.  There is no prospectively planned 
power for conclusive inference with regards to differences between desmopressin and placebo (or 
FE 201836).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 24 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049175] at the V 2-receptor  for treatment of nocturia due to NP.  
1.3 Benefit / Risk Aspects  
Benefits  
Subjects enrolled in the present  trial will be closely monitored and they will have the same or more 
frequent visits to the hospi[INVESTIGATOR_765353] t o routine  treatment, depending on local practice. During 
these visits the subjects will be given instructions regarding lifestyle changes (including limiting 
fluid intake ). For some subjects the implementation of lifestyle changes might  be enough to reduce  
bothersome nocturia, defined as [ADDRESS_1049176] . 
An improved safety profile is expected to result from this combination of characteristics. The short 
half-life of FE  201836 (approximately  2 hours) and low degree of unchanged renal excretion 
(approximately  5%) are designed to limit the antidiuretic effect  to the night -time sleep period, when 
subjec ts do not drink or their fluid intake is limited to a minimum  (to satisfy thirst  only). Therefore, 
the risk for dilutional hyponatraemia that may occur after the subjec t starts drinking in the morning 
is expected  to be l ow. 
Subjects in the phase 1 clinical trial 000195 were dosed with up to 48 00 ¬µg (i.e. , 9.6 times higher 
than the suggested maximum dose in the present phase 2 trial ) orally without any subject being 
hyponatr aemic.  Pharmacokinetic/pharmacodynamic (PK/PD ) modelling suggests that the duration 
of antidiuretic  effect at 500  ¬µg will be approximately  6 hours, limiting the potential for daytime 
antidiuresis.   
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 25 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  In the present trial, the risk of subjects developi[INVESTIGATOR_765344] a serum 
sodium monitoring plan , as described in Section  [IP_ADDRESS] . The plan  includes a [ADDRESS_1049177] ( IMP). Moreover, safety including  the occur rence of adverse events and clinically 
significant changes in laboratory value s (including serum sodium values) will be monitored 
throughout the trial.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 26 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  2 TRIAL OBJECTIVES AND ENDPOINTS  
2.1 Objectives  
Primary Objective  
‚Ä¢ To establish th e dose -response of FE [ADDRESS_1049178] to the number of nocturnal voids 
in subjects wi th nocturia due to  NP. 
Secondary Objectives  
‚Ä¢ To evaluate responder rates with regards to changes in number of nocturnal voids.  
‚Ä¢ To psychometrically validate the Nocturia Impact Diary¬© (NI Diary).  
‚Ä¢ To evaluate the patient benefit of FE 201836 based on the NI Diary data.  
‚Ä¢ To evaluate the clinical benefit of FE 201836 based on reduction in nocturnal voiding.  
‚Ä¢ To evaluate FE [ADDRESS_1049179] Undisturbed 
Sleep Period ( FUSP) and sleep related Patient Reported Outcomes (PROs).  
‚Ä¢ To evaluate the PD effect of FE [ADDRESS_1049180] to nocturnal diuresis rate and NP.  
Safety Objective  
‚Ä¢ To evaluate the safety profile of FE  201836.  
Exploratory Objectives  
‚Ä¢ To explore the biomarker c opeptin, an AVP surrogate, to identify low nocturnal vasopress in 
levels in plasma.  
‚Ä¢ To explore the dose -response of FE [ADDRESS_1049181] to total sleep time.  
‚Ä¢ To explore the association between total sleep time and FUSP.  
‚Ä¢ To explore the effect of FE [ADDRESS_1049182] to Nocturnal Polyuria i ndex ( NPi). 
‚Ä¢ To benchmark t he efficacy of FE 201836 in relation to desmopressin.  
2.2 Endpoints  
Primary Endpoint  
‚Ä¢ Change from b aseline in number of nocturnal voids during 12  weeks of treatment.  
Secondary Endpoints  
‚Ä¢ Change from b aseline in number of nocturnal voids at Weeks 1, 4, 8 and 12.  
‚Ä¢ Responder rate defined as 50% reduction in nocturnal voids  from baseline at Weeks 1, 4, 8 
and 12 during 12  weeks of treatment.  
‚Ä¢ Change from b aseline in NI Diary Total Score at Weeks 1, 4, 8 and 12 and during 12  weeks 
of treatment.  
‚Ä¢ Percentage of nights durin g the treatment period with at most one nocturnal void.  
‚Ä¢ Percentage of nights during the treatment period with complete response, i.e. , with no 
nocturnal voids.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 27 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Change from b aseline in NI Diary Overall Impact Score at Weeks 1, 4, 8 and 12 and during 
12 weeks of treatment.  
‚Ä¢ Patient Global Impression of Improvement (PGI -I) urinary symptoms scores at Weeks 1, 4, 
8 and 12.  
‚Ä¢ Change from b aseline in Patient Global Impression of Severity (PGI -S) scores at Weeks  1, 
4, 8 and 12.  
‚Ä¢ Change from b aseline in Bother as  measured by [CONTACT_765376] 5 -point Likert Bother scale  
(Hsu, 2015) at Weeks  1, 4, 8 and 12.  
‚Ä¢ Change from b aseline in Insomnia Severity Index (ISI) at We eks 4, 8 and 12.  
‚Ä¢ Change from b aseline in FUSP at 1, 4, 8 and 12 weeks of treatment and during 12  weeks.  
‚Ä¢ Change from b aseline in nocturnal diuresis rate (hourly) profiles at Week  1 and Week  12. 
‚Ä¢ Change from b aseline in Nocturnal Urine Volume (NUV) at Week 1 and Week  12. 
Safety Endpoints  
‚Ä¢ Incidence and severity of adverse events.  
‚Ä¢ Incidence of hyponatraemia as measured by [CONTACT_765377].  
‚Ä¢ Change from baseline  in mean 24 -hour urine volume at Week 1 and Week  12. 
‚Ä¢ Clinically significant changes in vital signs and laborato ry values.  
Exploratory Endpoints  
‚Ä¢ Responder rates defined as 33%, 60%, 70%, 80%, 90% and 100% reduction  from baseline 
in number of nocturnal voids at Weeks 1, 4, 8 and 12.  
‚Ä¢ Responder rates defined as 1, 2, and 3 voids reduction  from baseline in number of noc turnal 
voids at Weeks 1, 4, 8 and 12.  
‚Ä¢ The c orrelation of c opeptin levels to NPi [CONTACT_293778]  2. 
‚Ä¢ Change from b aseline in c opeptin  levels at Week  12. 
‚Ä¢ Change from b aseline in total sleep time  per night at Weeks 1, 4, 8 and  12 and during 
12 weeks of treatment.  
‚Ä¢ Correlation between change from b aseline in total sleep time and FUSP at Weeks  1, 4, 8 
and 12. 
‚Ä¢ Change from b aseline in NPi [CONTACT_314811]  1 and Week  12. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 28 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  3 INVESTIGATIONAL PLAN  
3.1 Overall Trial Design  
3.1.1 Trial Design Diagram s 
A trial overview is presented in Figure 3-1. Overviews of trial visits and electronic diary ( e-Diary ) 
assessments and questionnaires to be completed by [CONTACT_765385] 3-2 and Figure 3-3. 
 
a A sample of  subjects  (f rom trial sites in the US A) who have completed  the trial will participate, by [CONTACT_756], in an exit interview within 
14 days of  attending Visit  8. 
Figure 3-1 Trial Overview  
 Screening (1 Day)
Lifestyle Changes 
2 weeksVisit 1
Active Run -in
1 weekVisit 2
Washout
1 weekVisit 3
Randomised 
Treatment
12 weeksVisits
4-7
End-of-Trial
Exit InterviewaVisit 8
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 29 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049183] Prior to Randomisation  
 
 
V1
Reminder
CallDiary Training 5 DaysMinimum 2 weeks Lifestyle ChangesScreening
7 Days Active Run- in 7 Days Washout
V:Visit
*R*: Randomisation
ISI: Insomnia Severity Index
PGI-S: Patient Global Impression ofDisease Severity
IMP: Investigational Medicinal Product
NI Diary : Nocturia Impact Diary¬©
Bother: Hsu 5-point Likert Bother ScaleEnrichment Period
Void
Diary
V2-3
Days
to V2-2
Days
to V2-1
Days
to V2
NI
DiaryNI
DiaryNI
DiaryIMP IMP
ISI
IMP-4
Days
to V2
PGI-S
V3
-3
Days
to V3-2
Days
to V3-1
Days
to V3
IMP IMP IMP IMP-4
Days
to V3
V4
-3
Days
to V4-2
Days
to V4-1
Days
to V4
Day 1
PGI-S*R*
IMPI[INVESTIGATOR_765354]-4
Days
to V4
NI
DiaryNI
DiaryNI
Diary
BotherVoid
DiaryVoid
DiaryVoid
Diary
Void
DiaryVoid
DiaryVoid
DiaryVoid
DiaryVoid
DiaryVoid
DiaryVoid
DiaryVoid
DiaryVoid
Diary
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 30 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049184] During the Randomised T reatment  Period  
 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 31 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  3.1.2 Overall Design and Control Methods  
This is a randomised, double -blind, placebo -controlled, response -adaptive, dose -finding trial 
investigating the efficacy, safety and tolerability of 6 different oral doses ( 50-500 ¬µg) of 
FE 201836, with desmopressin as a benchmark, during 12  weeks of treatment for nocturia due to 
NP in adults.  
The trial will comprise  8 visits (Section 3.1.1 ) to the  clinic and will consist  of a 2 -week 
screening/lifestyle changes period  where no IMP will be given, an enrichment period consisting of 
a 1-week single -blind (to subjects) active run -in period and a [ADDRESS_1049185]  (Figure 3-1). During the active 
run-in period the trial subjects will receive 500  ¬µg FE 201836 and placebo to assess safety and 
establish that subjects who respond to treatment with FE  201836 are included in the trial (i.e., an 
enrichment design).  
The 12 -week double -blind randomised treatment period of the trial will follow  a response -adaptive 
Bayesian top -down design. Initially subjects will be randomised to: placebo, 500  ¬µg FE  201836 or 
desmopressin (for benchmarking only). When approximately [ADDRESS_1049186] been ran domised to 
the trial, an interim analysis will be conducted  to investigate the efficacy of  500 ¬µg FE  201836 . If 
500 ¬µg FE  201836 is not sufficiently efficacious compared to placebo the trial will be stopped for 
futility. If 500  ¬µg FE  201836 is efficacious additional doses of FE  201836 (doses 50 -350 ¬µg) will 
be opened up for randomisation of new subjects in  order to identify the Minimum Effective Dose 
(MED) and near maximal Effective D ose (ED 85). The ED [ADDRESS_1049187] 
85% of the effect of the maximum dose (500  ¬µg). After  the first interim analysis, subsequent 
interim analyses will take place every [ADDRESS_1049188] interim analysis  eligible subjects will be randomised to one of 8 treatment groups  
(Table 5-1). Each subject will be instructed to take the IMP every night at bedtime with the 
intention to sleep. In order to keep the treatment blinded each subject will receive two medications 
throughout the trial; an oral solution and an ODT , i.e., a double -dummy design will be applied 
because desmopressin is available in an ODT  formulation and FE  201836 is an oral solution (Table 
5-1). 
Subjects will be asked to follow lifestyle changes (e.g. , limiting fluid intake) througho ut the entire 
duration of the trial. In addition, subjects will be asked to complete e-Diary  assessments 
(Section  7.1.1 ) and PRO questionnaires (Section [IP_ADDRESS] ) before  and after randomisation  
(Figure 3-2 and Figure 3-3). One objective of the present trial is to further validate the NI Diary. 
Therefore, a sample of subjects (from trial sites in the US A) who have completed the trial will be 
invited to participate in an exit interview within 14 days of attending  the end -of-trial visit (Visit  8), 
to record the subjects‚Äô perception of what constitutes a meaningful change in the NI Diary Total 
Score (Section  10.3.1 ). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 32 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Safety, including serum s odium levels (Section  [IP_ADDRESS] ), adverse  events and clinically significant 
changes in vital signs and laboratory values will be monitored throughout  the trial  and reviewed on 
an ongoing basis by a Safety Review Committee (SRC) (Section  3.4).  
Furthermore, the risk for subject s developi[INVESTIGATOR_765355] a serum sodium 
monitoring plan  (Section  [IP_ADDRESS] ), including a 1-week active run -in to identify subjects at increased 
risk for developi[INVESTIGATOR_765345] . If the incidence of serum sodium 
levels <130  mmol/L is statistically significantly >10% during the active run -in, the Data Monitoring 
Committee ( DMC) established for the trial (Section  3.4) will  be notified and further action will be 
discussed, e.g., the DMC may recommend that the highest dose of FE  [ADDRESS_1049189] trial visit ( Visit 1, screening)  for the first subject is expected in Q [ADDRESS_1049190] is expected in Q3 2019. The total duration of the trial (for a subject) is 
expected to be approximately 1 8 weeks  (includi ng the exit interview) . 
Trial completion is defined as when  the last subjec t has  completed the  last visit in the randomised 
trial period  (Visit  8). 
3.2 Planned Number of Trial Sites and Subjects  
The trial will be conducted at approximately 70 sites in Europe  and North America . A maximum of  
300 subjects  will be included  (Section  9.1). 
3.[ADDRESS_1049191] been randomised  in a 
2:2:[ADDRESS_1049192] s, the allocation ratio is 2:7:1 for placebo, active treatment 
and desmopressin, respectively.  Subsequent interim  analyse s will be performed  every 8  weeks , 
where the randomisation allocation probabilities to FE  201836 doses will be adjusted . 
The interim a nalyses are detailed in  Section  9.11. 
3.4 Safety Review and Data Monitoring Committee s 
Trial data will be reviewed on an ongoing basis by [CONTACT_765386]. 
In addition , an internal DMC will be established for the  trial. The main purpose of the DMC i s to 
perform pre -planned interim analyses (Section  3.3) and make recommendations based on  review of 
the efficacy and safety data . An additional purpose of the DMC is to address any potential safety 
concerns raised by [CONTACT_12217]. The responsibilities  and the composition of the DMC are provided in a 
separate charter document.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 33 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  3.5 Discussion of Overall Trial Design and Choice of Control Groups  
3.5.1 Trial Design  
The present clinical trial includes a 2 -week period of lifestyle changes. Lifestyle changes (e.g., 
limiting fluid intake ) are recommended as an initial treatment in most clinical guidelines , e.g., the 
updated American Urology Association ( AUA ) guideline on the management of BPH 
(McVary,  2011), despi[INVESTIGATOR_765356] ( Weiss,  2013). Excluding pel vic 
floor exercises for bladder -related Lower Urinary Tract Symptoms ( LUTS ), which are not part of 
the present trial, there seems to be no evidence that prolonged lifestyle changes, versus the 
proposed [ADDRESS_1049193] subjec ts with nocturia primarily due to the underlying condition of NP driven with 
increased Free Water Clearance (FWC), who will benefit the most from treatment with an 
antidiuretic agent, a 1 -week ac tive run -in period followed by a 1 -week washout period will be 
applied to ensure that drug -responders (defined as subjects with a reduction of nocturnal diuresis 
rate [mL/min] of 20% or more) are identified.  
The ‚â•20% decrease in the nocturnal diuresis rate  has been established as a relevant marker of 
antidiurectic responsivenes in previous nocturia trials with an active run -in (Lose,  2003; 
Mattiasson, 2002 ). The NUV  is defined as the total urin e volume from [ADDRESS_1049194] is in nocturnal diuresis. The nocturnal diuresis rate  is 
calculated fro m the mean of 3 days NUV  and total time in bed:  
ùëÅùëúùëêùë°ùë¢ùëüùëõùëéùëô  ùëëùëñùë¢ùëüùëíùë†ùëñùë†  ùëüùëéùë°ùëí  (ùëöùêø/ùëöùëñùëõ )=NUV  (mL)
Total  Time  in Bed (min) 
The majority of fluid output occurs via the urine, approximately 1500 mL/day, therefore threre is 
no evidence in adult nocturia subjects that the relative change over the time in nocturnal diuresis 
rate ( mL/min  normalised to time in bed ) should be adjusted for body weight and or/body surface 
area which are  both assumed to be constant over a short period of [ADDRESS_1049195] (desmopressin) was a significant predictor for 
subsequent decrease from baseline in the number of nocturn al voids  (Yamaguchi, 2013 ). 
The underlying pathophysiologic mechanism of NP can be driven by [CONTACT_765387], which 
based on mode of action will be responsive to antidiuretic treatment, or by [CONTACT_765388] e, which differs substantially in mode of action and is governed by [CONTACT_765389] (ANP) which is directly and indirectly influenced by [CONTACT_765375] -Angiotensin -Aldosterone 
System (RAAS).  
The aim of the active run -in is (after excluding all other  medical causes of NP) to identify subjects 
with increased FWC , which is responsive to V 2-receptor agonism. In addition, safety will be 
assessed in this period with special emphasis on hyponatraemia.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 34 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049196] will 
receive two medications throughout the trial; an oral solution and an ODT , i.e., a double -dummy 
design will be applied because desmopressin is available i n an ODT formulation and FE  [ADDRESS_1049197] overseas trials  (with desmopressi n) in early 2000 
(Lose,  2003; Mattiasson, 2002 ; van Kerrebroeck, 2007 ). It is therefore reasonable and appropriate 
to use reduction in number of nocturn al voids from baseline as the primary endpoint in this trial.  
Nocturia is one of the primary causes of sleep disturbance and has been shown to impair 
functioning, quality of life, health and productivity, with those experiencing 2 or more voids per 
night reporting significant bother ( Ancoli -Israel, 2011 ). Awakening during the first [ADDRESS_1049198] restorative sleep is more likely to contribute to daytime 
fatigue ( Chartier -Kastler, 2006 ). The clinically relevant benefit (for the subject) of desmopressin 
treatment may be demonstrated further by [CONTACT_765390] ( FUSP ), 
which reduces  the time spent in slow wave (deep) sleep ( Bliwise, 2015 ). Therefore it is reasonable 
to include FUSP as an endp oint in the present trial . To further evaluate the clinical benefit of 
FE [ADDRESS_1049199] of nocturia and its treatment on subjects‚Äô quality of life and daily lives will 
be documented by [CONTACT_2224] a n e-Diary which contains a 3-day voiding diary, NI Diary and PRO 
questionnaires. Voiding diaries are standard tools use d within the urology area 
(Holm -Larsen,  2009) and  are among the best possible means of obtaining objective data on 
subjective  symptoms ( Abrams, 1983 ). A voiding diary therefore represents a self -monitoring daily 
record of the individual‚Äôs voiding behaviour. The ICS recommends inclusion of voiding diaries in 
clinical assessment of subjec ts with LUTS  (Abrams,  2002). The subjects will be asked to complete 
voiding diaries over [ADDRESS_1049200] been shown to be as effective as 7 -day diaries with the 
potential for better accuracy ( Dmochowski,  2005). 
The NI Diary, is a 12-item PRO measure assessing t he impact burden associated with nocturia 
(Holm -Larsen, 2014 ). The NI Diary has been developed and psychometrically evaluated in patients 
with nocturia, in line with published International Society for Quality of Life Research (ISOQOL) 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 35 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  and International Society for Pharmacoeconomic and Outcomes Research (ISPOR) gui dance 
(Patrick, 2011 ; Reeve, 2013 ), as well as the Food and Drug Administration  (FDA ) Guidance for 
Industry, Patient -Reported Outcome Measures, 2009  (FDA, 2009 ). 
The PGI -S and PGI-I questionnaires , developed for use in populations with urinary tract conditions 
(Viktrup, 2012 ; Yalcin,  2003), are included to support anchor -based analysis of the NI Diary , as 
described in Section  10.3.1 . 
To further assess the change in subjective bothersomeness  of nocturia, trial participants will be 
asked, ‚ÄúHow much has this frequency of night -time urination bothered you?‚Äù with response options 
including ‚Äúnot at all,‚Äù ‚Äúslightly,‚Äù ‚Äúmoderately,‚Äù ‚Äúquite a bit,‚Äù and ‚Äúextremely.‚Äù This 5 point Likert 
scale has previo usly been used i n a large epi[INVESTIGATOR_119262] (Hsu, 2015). 
The ISI is a PRO  instrument  to quantify the subject's perception of his/her insomnia severity, it is 
included as a measure of sleep quality. The  ISI targets the subjec tive symptoms and consequences 
of insomnia as well as the degree of concern or distress caused by [CONTACT_765391] ( Bastien, 2001 ). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 36 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  4 SELECTION OF TRIAL POPULATION  
4.1 Trial Population  
The tria l population will be adult male and  female subjects  with nocturia due to NP , approximately 
50% of each gender,  who fulfil the eligibility criteria listed below.  
4.1.[ADDRESS_1049201] meet the following inclusion criteria between Visit 1 (screening) through Visit  4 
(randomisat ion): 
1. Written informed consent prior to performance of any trial -related activity  
2. Adults ‚â•18 years of age (at the time of written consent)  
3. Female subjects  of child-bearing potential must be willing and able  to use  adequate 
contraception throughout  the trial. D ocumentation of an acceptable  effective method  of 
contraception  must be available . All pre - and perimenopausal subjects have to perform 
pregnancy tests. Amenorrhea of more than [ADDRESS_1049202] reported nocturia symptoms during the 6 months prior to Visit  1 
5. ‚â•2 nocturnal voids (an average over 3 days) as documented in  the [ADDRESS_1049203] be ‚â•200 mL (at least 1 void ‚â•200 mL) as documented in 
the 3-day e -Diary prior to Visit 2  
7. Nocturnal polyuria, defined as NPi >33%, a ratio of NUV in excess of 33% of total daily 
(24-hour) urine volume as documented in the 3-day e -Diary prior to Visit  2 
8. b 
9. ‚â•20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit  2) as 
documented in the [ADDRESS_1049204] ‚â•2 nocturnal voids (an 
average over 3 days) as documented in the 3-day e -Diary prior to Visit  4 
                                              
b Original inclusion criterion omitted as per Clinical Trial Protocol Amendment 02 (applicable for all trial sites).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 37 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049205] meeting one or more of the following exclusion criteria between Visit 1 (screening) 
through Visit 4 (randomisation) will be considered as a screening failure : 
1. Current diagnosis of Obstructive Sleep Apnoea (OSA)  
2. Restless Legs Syndrome (RLS)  
3. Bladder Outlet O bstruction (BOO) or urine flow <5 mL/s , as confirmed by [CONTACT_765392][INVESTIGATOR_765357] 2   
4. Urinary incontinence defined as an average of >1 epi[INVESTIGATOR_1865]/day in the 3 -day e-Diary prior to 
Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not 
necessarily  exclusionary)  
5. c 
6. Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation  
within t he past [ADDRESS_1049206] pathology that can in the i nvestigator‚Äôs opi[INVESTIGATOR_765347] e.g., symptomatic or recurrent urinary tract infections, interstitial 
cystitis, bladder -related pain, chronic pelvic pain syndrome, or stone in the bladder or  urethra 
causing symptoms  
8. A history of cancer with the last date of disease activity/prescence of malignancy within the last 
12 months  prior to Visit  1, except for adequately treated basal cell carcino ma of the skin 
9. History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple 
Sclerosis, Parkinson‚Äôs, spi[INVESTIGATOR_1828], spi[INVESTIGATOR_113163])  
10. Habitual (fluid intake >3L per day) or psychogenic polydipsia  
11. Uncontrolled hypertensi on, as judged by [CONTACT_093]  
12. a 
13. Uncontrolled diabetes mellitus , as judged by [CONTACT_093]  
14. Central or nephrogenic diabetes insipi[INVESTIGATOR_27562]  
15. Known history of Syndrome of Inappropriate Antidiuretic H ormone  (SIADH) secretion  
16. History of g astric retention  
17. Suspi[INVESTIGATOR_765348], ([LOCATION_001] Heart Association [NYHA] class 
II, III, IV)  
                                              
c Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites).  
a Origina l exclusion criterion omitted as per Clinical Trial Protocol Amendment 01 (applicable for all trial sites).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 38 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  18. Hyponatraemia:  
‚Ä¢ Serum sodium level <1 35 mmol/L at Visit  1(re-tested, with results available within 7  days)  
‚Ä¢ Serum so dium level <130 mmol/L at Visit  3 (re-tested, with results available within 7  days)  
19. Hepatic and/or biliary diseases:  
‚Ä¢ Child -Pugh Class A, B, or C  
or 
‚Ä¢ Aspartate aminotransferase and/or al anine aminotransferase levels >3 x the upper limit of 
normal range  as well as total bilirubin level >2x the u pper limit of normal range  
20. Known history of  hypersensitivity to desmopressin ODT  
21. Pregnancy, breastfeeding, or a planning to become pregnant during t he period of the trial   
22. Known alcohol or substance abuse  
23. Work or lifestyle that may interfere with regular n ight-time sleep e.g. , shift workers  
24. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, 
or language barrie r that, in the judgment of the i nvestigator, would impair participation in the 
trial 
25. d 
26. Previous participation in a nocturia, Benign  Prostatic Obstruction (BPO ), or OAB clinical trial 
within the past [ADDRESS_1049207] ly or indirectly with the trial  
28. Use of any restricted therapy not in accordance with the protoco l 
29. Use of any prohibited therapy listed below:  
‚Ä¢ Current or former (within 3 months prior to screening) treatment with any other IMP  
‚Ä¢ Unstable electrostimulation or behavioural bladder training program less than 3 months 
prior to screening (stable electrostimulation or behavioural bladder training program started 
at least 3  months before screening are acceptable)  
‚Ä¢ Thiazide diuretics  
‚Ä¢ Antiarrhythmi c agents  
‚Ä¢ V2-receptor antagonists/agonists  (e.g., vaptans/desmopressin, vasopressin)  
‚Ä¢ Loperamide  
                                              
d Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 39 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Botulinum toxin (cosmetic non -urological use is acceptable)  
‚Ä¢ Valproate  
4.[ADDRESS_1049208]  given written informed consent  will receive a unique (site -specific) screening 
number and be invited to  perform  a screening visit  (Visit 1) . 
All screening assessments must be completed and evaluated to confirm that all eligibility criteria  
are met  by [CONTACT_423] . A site-specific Screening L og, for record ing of  details of all subjects 
screened and confirmation of eligibility or record ing of reasons for s creening failure , as applicable , 
must be maintained at the trial site.  The screening number , whic h will be allocated sequentially in 
the order in which the subjects are screened , must be entered into the Screening L og. 
It is permitted to re -screen a subject in this trial in case a subject has been considered a screening 
failure due to one or more of the following reasons:  
‚Ä¢ not fulfilling the inclusion criterion number 6  as defined in Clinical Trial Protocol versions 
2.0 (>250 mL) , 3.0 (>250 mL) , or 4.0 (‚â•250 mL)  but had at least 1 single voided volume 
‚â•200 mL prior to Visit 2  
‚Ä¢ not fulfilling the inclusion criterion  of an NI Diary Total Score of ‚â•10 points (raw score) 
prior to Visit 2 (inclusion criterion number 8) as defined in Clinical Trial Protocol versions 
2.0 and 3.0  
‚Ä¢ fulfilling the exclusion criterion of a serum triglyceride level >400 mg/dL (exclusion 
criterion number 12) as defined in Clinical Trial Protocol version 2.0  
‚Ä¢ fulfilling the exclusion criterion of aspartate aminotransferase and/or alanine 
aminotransferase levels >2x the upper limit of normal range and a total bilirubin level 
>1.5 mg/dL (second part of exclusion criterion number 19) as defined in Clinical Trial 
Protocol version 2.0  
‚Ä¢ fulfilling exclusion criterion number 3 as defined in Clinical Trial Protocol version s 2.0, 3.0, 
and 4.0  
‚Ä¢ fulfilling exclusion criterion number 5 as define d in Clinical Trial Protocol version s 2.0, 3.0, 
and 4.0  
‚Ä¢ fulfilling exclusion criterion number 25 as defined in Clinical Trial Protocol version s 2.0, 
3.0, and 4 .0 
‚Ä¢ technical issues with the e -Diary device prior to Visit [ADDRESS_1049209] not be re -screened for 
participation in the trial at a later time.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 40 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049210] 50% of subjects should be randomised at trial sites in 
the [LOCATION_003]  to allow for an optimised validation of the NI Diary. Therefore, a cap of maximum 
[ADDRESS_1049211] s will be randomised to treatment in a fixed manner. The allocation r atio is 
2:2:[ADDRESS_1049212] interim analysis, after 
125 subjects being randomised , the allocation ratio is 2:7:[ADDRESS_1049213] s will continue without any stop at the interim analyses.  For more information regarding 
the interim analyses, please refer t o Section  3.3 and Section  9.11. 
The screening rate will be monitored such that the a ccrual of randomised subjects  does not 
overshoot the operating characteristics described in Section  9.1, which could potentially result in a 
loss of statistical power.  
[IP_ADDRESS]  Randomisation i f Maxim um Dose is Lowered  
The trial has been designed with the option to decrease the maximum dose of FE  201836 from 
500 ¬µg to 350  ¬µg if recommended  by [CONTACT_1363]  (Section  9.11.1 ). If this decision is made, 
randomisation to the [ADDRESS_1049214] not completed the trial , the DMC will recommend  whether or 
not these  subjects may be permitted to remain on treatment with 500 ¬µg FE 201836 for the 
remainder of the trial. Subjects randomised to treatment with  500 ¬µg FE  201836 who prematurely 
discontinue  the trial due to DMC decision (Section  4.4) may be replaced by [CONTACT_1130] s randomised to 
treatment with a lower dose of FE  201836.  
If the decision to close randomisation to [ADDRESS_1049215] been randomised,  the remaining subjects will be 
randomised to the following treatment groups: placebo, desmopressin (25 ¬µg for females and 50  ¬µg 
for males) or [ADDRESS_1049216] interim analysis  the do se-response adaptive 
randomisation will allocate sub jects to the remaining 7 open treatment groups : placebo, 50  ¬µg 
FE 201836, 100  ¬µg FE 201836, 150  ¬µg FE 201836, 250  ¬µg FE 201836, 350  ¬µg FE 201836 , or 
desmopressin (25 ¬µg fo r females and 50 ¬µg for males).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 41 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  4.3 Restrictions  
4.3.1 Prior and Concomitant Therapi[INVESTIGATOR_765358]/therapi[INVESTIGATOR_765359]  (eCRF ) at screening  
(Visit  1). Any c hanges (including new therapi[INVESTIGATOR_014]) must be recorded at each subsequent visit. 
Any therapy for treat ment of  nocturia or sleep disorders (e.g., guidance for lifestyle changes, pelvic 
floor muscle training, electrostimulation, biofeedback treatment) that a subject received before trial 
initiation should be continued without any change throughout the trial period.  All subjects must 
have normal serum sodium (‚â•135 mmol/L) at screening and serum sodium levels will be monitored 
throughout the trial as described in Se ction 6.1 (Table 6-1) and Section [IP_ADDRESS] . 
The following medications will be permitted, provided that t he subject has been on a stable dose for 
the 3 months prior to the screening visit (Visit  1) (i.e., treatment has not been initiated or 
discontinued and there has been  no change in dose):  
‚Ä¢ Sedative/hypnotic medications for sleep disorders  
‚Ä¢ Selective Serotoni n Reuptake Inhibitors (SSRIs): citalopram, duloxetine, venlafaxine, 
escitalopram, paroxetine, fluoxetine, sertraline  
‚Ä¢ Chronic use of Non -steroidal Anti -inflammatory Drugs (NSAIDs)  
‚Ä¢ Chlorpromazine  
‚Ä¢ Medicines used for treatment of BPH such as alpha -blockers (d oxazosin, tamsulosin, 
terazosin  and alfuzosin) and 5 -alpha -reductase inhibitors (e.g., dutasteride  and finasteride)  
and phosphodiesterase -5 inhibitors (e.g., tadalafil)  
‚Ä¢ Medicines used for treatment of OAB such as antimuscarinic therapy (tolterodine, 
fesoterodine, oxybutynin, darifenacin, hyoscyamine, trospi[INVESTIGATOR_1890], solifenacin)  and beta-[ADDRESS_1049217] s (mirabegron)  
‚Ä¢ Sulfonylurea, including chlorpropamide  
‚Ä¢ Loop diuretics (furosemide, torsemide, ethacrynic acid) and other classes of diuretics 
(triamterene, chlorthalidone, amiloride, indapamide) are permitted, either as monotherapy or 
combination therapy  if the subject takes  the loop diuretic  prior to 4  pm (the timing of this 
treatment regimen  must have been in place for at least 1 week prior to the screening  visit 
[Visit  1]) 
‚Ä¢ Systemic corticosteroids  
‚Ä¢ Carbamazepi[INVESTIGATOR_050]  
‚Ä¢ Lithium  
‚Ä¢ Opi[INVESTIGATOR_2438]  
‚Ä¢ Lamotrigine  
‚Ä¢ Tricyclic antidepressants  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 42 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Additional serum sodium monitoring should be performed as described in Section [IP_ADDRESS]  if 
treatment with the following medications is initiated or dosing is increased during the trial:  
‚Ä¢ SSRIs: citalopram, duloxetine, venlafaxine, escitalopram, paroxetine, fluoxetine, sertraline  
‚Ä¢ Chronic use of NSAIDs  
‚Ä¢ Chlorpromazine  
‚Ä¢ Sulfonylurea, including chlorpropamide   
‚Ä¢ Loop diuretics (furosemide, torsemide, ethacrynic acid) and other classes of diuret ics 
(triamterene, chlorthalidone, amiloride, indapamide)  
‚Ä¢ Systemic corticosteroids  
‚Ä¢ Carbamazepi[INVESTIGATOR_050]  
‚Ä¢ Lithium  
‚Ä¢ Opi[INVESTIGATOR_2438]  
‚Ä¢ Lamotrigine  
‚Ä¢ Tricyclic antidepressants  
‚Ä¢ Any other drug that increases the risk of hyponatraemia  
4.3.2 Prohibited Therapy  
The following medications a re prohibited throughout the duration of the trial (exclusion criterion 
number  29, Section  4.1.2 ): 
‚Ä¢ Current or former (within 3 months prior to the screening  visit [Visit  1]) treatment with any 
other IMP  
‚Ä¢ Unstable electrostimulation or behavioural bladder training program less than 3  months 
prior to the screening visit (Visit  1) (stable electrostimulation or behavioural bladder 
training program started at least 3 months prior to  the screening visit are acceptable)  
‚Ä¢ Thiazide diuretics  
‚Ä¢ Antiarrhythmic agents  
‚Ä¢ V2-receptor antagonists/agonists  
‚Ä¢ Loperamide  
‚Ä¢ Botulinum toxin (non -urological use is a cceptable)  
‚Ä¢ Valporate  
Any new therapy for treat ment of  nocturia or sleep disorders must not be initiated throughout the 
duration of the trial. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 43 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  4.3.3 Lifestyle Changes and Other Restrictions  
In order to prevent hyponatraem ia and to avoid interference with efficacy  assessment of the 
treatment : 
‚Ä¢ The fluid intake must be limited to a minimum  (to satisfy thirst  only)  during the time 
interval of 1 hour before , until 8 hours after administration of IMP 
‚Ä¢ The subject should empty the bladder before going to bed with the intention to sleep  
‚Ä¢ The treatment should be interrupted during acute intercurrent illnesses characterised by [CONTACT_765393]/or electrolyte imbalance (such as systemic infections, fever, gastroenteritis)  until the 
subject has fully recovered. The treatment can be re-started at the discretion of the 
investigator once the condition of the subject is stabilised  
Subjects will be reminded to follow instructions regarding lifestyle changes throughout the duration 
of the trial.  
Subjects participating in the present trial  should refrain from donating blood or sperm throughout 
the trial period.  
4.3.[ADDRESS_1049218]-menopausal is defined as amenorrhea 
of >[ADDRESS_1049219] menstrual period.  
In the context of this trial,  acceptable effective method s include:  
‚Ä¢ Transdermal patch  
‚Ä¢ Established use of oral, injected or implanted hormonal methods of contraception  
‚Ä¢ Placement of an intraute rine device (IUD) or intrauterine system (IUS)  
‚Ä¢ Barrier methods of contraception: condom or o cclusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository  
‚Ä¢ Male sterilisation (with the appropriate post -vasectomy documentati on of the absence of 
sperm in the ejaculate)  
‚Ä¢ True abstinence: When this is in line with the preferred and usual lifestyle of the subject  
Periodic abstinence (cale ndar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides onl y, and lactational amenorrhoea method (LAM) are not acceptable  
methods of contraception. Femal e condom and male condom should not be used together.  
Contraceptive measures will not be required for male subjects participating in the trial based on 
genotoxici ty data obtained in animal studies with FE  201836, as detailed in the Investigator‚Äôs 
Brochure.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 44 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049220] be withdrawn  from the trial in case of:  
‚Ä¢ Serum sodium level is ‚â§125 mmol/L  at any time point during the trial  
‚Ä¢ Significant non -compliance with the  trial protocol, as judged by [CONTACT_941] i nvestigator and/or the 
sponsor  
‚Ä¢ Other medical or sa fety reasons, as judged by [CONTACT_941] i nvestigator and/or the sponsor  
‚Ä¢ The subject wishe s to discontinue for any reason  
A subject  has the right to withdraw from the trial at any time for any reason, without the need to 
justify his/her  decision. However, the i nvestigator should record the reason for the subject‚Äôs 
withdrawal, if possible. The investigator also has the right to withdraw a subject . Since an excessive 
rate of withdrawals can render the trial devoid of meaning,  unnecessary withdrawal of subjects 
should be avoided.  
Every effort should be made to invite subjects withdrawn/discontinued from  the trial to an end -of-
trial v isit (Visit  8) as so on as possible after a decision of withdrawal/ discontinuation has been taken. 
For any discontinuation, the investigator should obtain the required information and document the 
date and reason for  the premature discontinuation in the eCRF.  
In case the subje ct has withdrawn consent, no new data can be recorded in the  eCRF. Correction of 
previous data and/or recording  data related to visits/procedures done prior to but made available 
after withdrawal of consent (e.g. , laboratory results) will be allowed unless  the subject disapproves 
it. 
If the reason for withdrawal is an adverse event, the specific event or the main laboratory 
abnormality must be recorded in the eCRF. The investigator should  make thorough efforts to 
document the outcome.  
Subjects discontinued from the trial will not be replaced , except for subjects randomised to 
treatment with  500 ¬µg FE  201836 in case a decision is taken to decrease the maximum dose of 
FE 201836 from 500  ¬µg to 350  ¬µg (Section  [IP_ADDRESS] ). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 45 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049221] will receive 2 medications  (double -dummy 
design) , an oral solution  and an ODT  formulation, during every treatment period  of the trial, as 
outlined in Table 5-1. 
During the a ctive run -in period all subjects will receive 500 ¬µg  FE 201836  oral solution (and 
placebo ODT ) for 1 week.  
After the lifestyle changes/screening, active run -in and w ashout periods, eligible subjects will be 
randomised  to a treatment group  as follows:  
‚Ä¢ Prior  to the first interim  analysis, the first 125 subjects will be randomised to  the following 
treatment groups : placebo , desmopressin or 500 ¬µg FE 201836.  
‚Ä¢ After the  first interim analysis , subjects may be randomised to one of 8 treatment groups: 
placebo, 50 ¬µg FE 201836, 100  ¬µg FE 201836, 150  ¬µg FE 2 [ZIP_CODE], 250  ¬µg FE 201836, 
350 ¬µg FE 201836, 500 ¬µg  FE 201836  or desmopressin (25 ¬µg for females and 50  ¬µg for 
males) . 
After randomisation, the duration of treatment is [ADDRESS_1049222] Interim Analysis    
500 ¬µg FE 201836  500 ¬µg FE 201836  oral solution  Placebo ODT  
Desmopressin  Desmopressin ODT  (25¬µg for females 
and 50 ¬µg for males)  Placebo oral solution  
Placebo  - Placebo oral solution and Placebo ODT  
After First Interim  Analysis    
50 ¬µg FE 201836  50 ¬µg FE 201836 oral solution  Placebo ODT  
100 ¬µg FE 201836  100 ¬µg FE 201836 oral solution  Placebo ODT  
150 ¬µg FE 201836  150 ¬µg FE 201836  oral solution  Placebo ODT  
250 ¬µg FE 201836  250 ¬µg FE 201836 oral solution  Placebo ODT  
350 ¬µg FE 201836  350 ¬µg FE 201836 oral solution  Placebo ODT  
500 ¬µg FE 201836  500 ¬µg FE 201836 oral solution  Placebo ODT  
Desmopressin  Desmopressin ODT  (25¬µg for females 
and 50 ¬µg for males)  Placebo oral solution  
Placebo - Placebo oral solution and Placebo ODT  
 
Each subject will be instructed to take the IMP every night at bedtime with the intention to sleep . In 
addition, as potential food interaction cannot be ruled out at this point in the development  of 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 46 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  FE 201836 , subjects participating in the present trial wi ll be instructed to wait for a minimum of 
2 hours after eating the main evening meal  before taking the IMP.  
5.2 Characteristics and Source of Supply  
All IMP  is provided by [CONTACT_480222] A/S and  will be handled according to the 
principles of G ood Manufacturing Practice (GMP).  Ferring Pharmaceuticals A/S will provide the 
trial sites with IMP in amounts sufficient for the trial.  
5.2.[ADDRESS_1049223] s 
The following IMP  will be used in the trial:  
IMP :    FE 201836  
Strength:    50, 100, 150, 250, 350 and 500 ¬µg 
Formulation:    Oral solution, bottle of 5  mL 
Administration method  For oral use  
IMP:     Desmopressin  
Strength:    25 ¬µg and 50  ¬µg 
Formulation:    ODT  
Administration method:  To be placed under the subject‚Äôs tongue, without water  
IMP:     Placebo  
Strength:    - 
Formulation:    Oral solution , bottle of 5  mL 
Administration method:  For oral use  
IMP:     Placebo  
Strength:    - 
Formulation:    ODT  
Administration method:  To be placed under the subject‚Äôs tongue, without water  
5.3 Packaging and Labelling  
Packaging and labelling of the IMP will be performed under the responsibility of the IMP 
department at Ferring Pharmaceuticals A/S in accordance with GMP and na tional regulatory 
requirements.  
The IMP will be labelled in a manner  that ensures  the treatment blinding of the trial  is maintained . 
The active drug and placebo are visually identical.  
The label of the IMP will contain one self -adhesive tear -off portion to be affixed to the Drug 
Dispensing Log  maintained at the trial site.  
5.4 Conditions for Storage and Use 
The investigator will ensure that the IMP is  stored under appropriate conditions in a secure location 
with controlled  access . The storage compartment shall be monitored regularly and the temperature 
shall be documented.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 47 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049224] be stored at 2 -8¬∞C (36-46¬∞F)  before dispensing. After 
dispensing, the products should be stored at room temperature.  
Desmopressin and placebo ODT  should be stored at 25¬∞C (77¬∫F); excursions permitted to 15 -30¬∞C 
(59-86¬∞F). The product should be kept in the original package to be protect ed from moisture and 
light. The product should be used immediately upon opening of the individual tablet blister.  
The investigator will ensure that the IMP is stored under appropriate conditio ns in a secure location 
with controlled access. The storage temperature shall be monitored regularly and documented in 
accordance with the instructions provided by [CONTACT_456]. Deviations in storage temperature must 
be reported to the sponsor as instructed  in the IMP handling instruction.  
Returned IMP from the subjects (used/partly used o r unused , including empty packag ing material) 
must be stored separately from non -allocated IMP.  
The subjects will be instructed to store the IMP in accordance  with the abov e-mentioned 
conditions.  
5.5 Blinding/Unblinding  
5.5.[ADDRESS_1049225] Treatment   
An emergency unblinding procedure will be available for the investigator a nd designated personnel  
at the s ponsor  through the eCRF . It is the investigator‚Äôs responsibility to decide whether it is 
medically necessary to know which IMP the subject receives (i.e., unblinding) to ensure the 
subject‚Äôs welfare and safety. Breaking of the blind for individual subjects in emergency situations is 
only permitted in case of a S uspected Unexpected Serious Adverse R eaction (S[LOCATION_003]R) , or in case 
of an adverse event where the knowledge of the IMP administered is required for medical 
management of the subject.  
As far as the emergency permits, the need to break the blind will be agreed by [CONTACT_458236]. The investigator who unblinds a treatment will use the  eCRF and is required to enter a 
password and must record the reason for unblinding before the treatment code can be broken. It 
must also be recorded in the eCRF when , and by [CONTACT_20898] , the code was broken. The investigator 
must record the event of unblinding i n the subject‚Äôs medical record , including the r eason for 
unblinding.  
If the s ponsor needs to unblind a treatment, the eCRF  will be used for unblinding . It is a 
requirement to enter a password and the reason for unblinding before the treatment code can be 
broken. It must also be recorded in the eCRF when and by [CONTACT_2185].  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 48 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049226]‚Äôs treatment sche dule for the purposes of 
expedited reporting to the authorities and/or Independent Ethics Committees (IECs)/ Institutional 
Review Boards ( IRBs )/Research  Ethics Boards (REBs) . In that situation, every effort should be 
made to m aintain blinding of the sponsor  personnel involved  in data analysis and interpretation. 
Other personnel may be unblinded for S[LOCATION_003]Rs, including trial site personnel as well as personnel  
acting on behalf of the sponsor.  
Information on whether the blind has been broken for any subjects  is available in the eCRF and  
must be collected before the database is declared clean and is released to the trial statistician.  
In case the eCRF cannot be accessed , and hence the emergency unblinding cannot be performed 
within the eCRF system, the investigato r should contact [CONTACT_765394]:  
Global Pharmacovigilance, Ferring Pharmaceuticals A/S  
Tel:  
5.6 Treatment Compliance  
5.6.1 Dispensing and Accountability  
The IMP will be handled by [CONTACT_765395].  
The IMP  for the active run-in will only be dispensed to subjects wh o meet the eligibility criteria at 
Visit 2. 
The IMP for the randomised treatment  period will only be dispensed to subjec ts wh o meet the 
eligibility criteria at Visit 4 and are randomised into the trial .  
The investigator (or his/her design ee) will maintain a Drug Dispensing Log detailing the dates and 
quantities of IMP dispensed to, and used by  [CONTACT_6992], as well as the batch number (s).  
Each subject should return all unused and used IMP bottles and ODT blister sheets (empty foils) to 
the trial site. The delegated designee at each trial site will reconcile all used and unused IMP and 
maintain  all IMP (including empty bottles and ODT blister/foils) for drug accountability.  The 
monitor will verify the drug accountability during the trial.  
5.6.2 Assessment of Compliance  
Treatment compliance will be verified at Visits 3, 5, 6,  7 and  8, by [CONTACT_765396], partly used 
and unused IMP and/or subject‚Äôs statements  documented in the source documents in  case the IMP  
is lost. 
5.[ADDRESS_1049227] er sheets. Used  and 
partly used IMP bottles and blisters (foils)  will be destroyed at the trial site according to local 
regulations and standard procedures at the site, after the drug accountability has been verified by 

[CONTACT_1782]: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 49 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  the monitor.  Any unused IMP will be returned for destruction, as instructed by [CONTACT_765397] A/S and in accordance with local requirements . 
Documentation on destruction will be forwarded to the s ponsor.  
[ADDRESS_1049228] receive a detailed explanation (verbal and written information) of the trial and must sig n an 
Informed Consent Form (ICF) after having had sufficient time to consider the participation in the 
trial. No trial -related procedures must be performed on the subject prior to signing the ICF. 
6.1 Trial Flow Chart  
The overall tr ial design is shown in Secti on 3.1. The assessments scheduled for each visit are 
presented in the  flow chart in Section  6.1, listed in Section s 6.2  to 6.7 and further described in 
Section  7. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 50 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 6-1 Trial Flow Chart  
Assessment  Screening/  
Lifestyle Changes  Active Run -in 
Period  Washout 
Period  Randomised Trial Period  
Visit (V)  V1 Reminder  V2 Telephone 
Follow -up V3 V4 L V5 V6 V7 V8 O 
Week        1 4 8 12 
Day/Visit  window  S1  -14 -10¬±1 m -7 n 1 8¬±2 28¬±3  56¬±3  84¬±7  
Inform ed consent  X          
Inclusion and exclusion criteria  X  X  X X     
Lifestyle Changes  a X X X X X X X X X  
Randomisation       X     
Dispense e -Diary  X          
e-Diary Training  X  b         
e-Diary Compliance    X  X X X X X X 
Dispense IMP    X   X X X X  
Accountability of IMP      X  X X X X 
Demographics  X          
Medical history  X          
Physical examination  X     X    X 
Body weight  X  X  X X X X X X 
Height  X          
Vital Signs c X  X  X X X X X X 
Electrocardiogram (ECG)  X         X 
Pregnancy test  - serum  d  X     X    X 
Pregnancy test - urine  d X          
Clinical chemistry, 
haematology, urinalysis  X     X X X X X 
Coagulation factors  X     X  X  X 
Copeptin    X   X    X 
OSA assessment  e X          
Serum sodium  p X j     X k, n  X X X X 
Voiding Diary f   X  X X X X X X 
NI Diary f   X   X X X X X 
PGI-S g   X   X X X X X 
PGI-I g       X X X X 
ISI h   X   X  X X X 
Bother h      X X X X X 
Exit Interview i           X 
Adverse events    X X X X X X X X 
Concomitant medication  X  X  X X X X X X 
a. Subjec ts will be reminded about lif estyle c hanges throughout the trial.  
b. Original f ootnote omitted as per Clinical Trial Protocol Amendment 0 3 (applicable f or all trial sites).   
c. Vital signs ( blood pressure and heart rate ) measured af ter resting f or 5 minutes in a sitting position.  
d. Applicable to all pre - and perimenopausal f emale subjects.  
e. Original f ootnote omitted as per Clinical Trial Protocol Amendment 0 3 (applicable f or all trial sites).  
f. Completed by [CONTACT_765398] [ADDRESS_1049229] . 
i. A sample of  subjects  (at trial sites in the [LOCATION_003] ) who completed the trial will be invited to participate, by [CONTACT_756], in an exit interview wi thin 
14 days of  attending Visit  8. 
j. If  serum sodium is <135mmol/L the test should be repeated within 7 days, if  the second result is <1 35mmol/L the subject must be discontinued 
f rom the trial as a ‚Äòscreening f ailure‚Äô. If  more than [ADDRESS_1049230] be re -tested, with results available prior to Visit 2.  
k. If  serum sodium is <130mmol/L the investigator must immediately contact [CONTACT_765399] f or f urther evaluatio n , if  the serum 
sodium is <130mmol/L (results conf irmed within 7 days) the subject will not be randomised to the trial an d must be discontinued f rom the trial 
as a ‚Äòscreening f ailure‚Äô.  
l. Baseline ef f icacy.  
m. During the 1 week active  run in period, 4 days (¬±1 day) af ter the planned start of  IMP treatment , the subject will be telephoned to f ollow up on 
saf ety.  
n. If  the subject canno t attend Visit [ADDRESS_1049231] the serum sodium level at Day 6-8 f rom the IMP start  date. 
o. The end -of-trial v isit (Visit 8) shoul d be perf ormed  if  the subj ect discontinues the trial prior to  Visit  8. 
p. Sample to be taken pref erably in the morning .  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 51 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049232] during the screening period:  
‚Ä¢ Signing of informed consent  
‚Ä¢ Allocation of a screening number  
‚Ä¢ Inclusion and exclusion criteria will be evaluated . 
‚Ä¢ Demographic data will be recorded.  
‚Ä¢ Information on medical history will be recorded based on review of the medical records and 
interview of the subject.  
‚Ä¢ Information on concomitant medication will be  recorded.  
‚Ä¢ Physical examination , including body weight and height , will be performed.  
‚Ä¢ Vital signs (blood pressure and heart rate) will be measured.  
‚Ä¢ Blood samples will be drawn for analysis of haematology , clinical chemistry (including 
serum sodium ) and coa gulation factors . 
‚Ä¢ Urine samples will be collected for urinalysis.  
‚Ä¢ Serum  and urine pregnancy test s will be performed in all pre - and perimenopausal  female 
subjects.  
‚Ä¢ Assessment of OSA.  
‚Ä¢ 12-lead electrocardiogram (ECG) will be measured.  
‚Ä¢ The e-Diary  will be dispensed. Subjects will be trained to complete the e -Diary and will be 
encouraged  to complete the diary  at home during 5 days for training  purposes . 
‚Ä¢ The subject will be given instructions about lifestyle changes and will be requested to 
maintain t hese lifestyle changes throughout the trial  (Section  4.3.3 ). 
The e -Diary training will be followed  by [CONTACT_765400]  (via the web -portal) .  
Prior to Visit  [ADDRESS_1049233] will be reminded to complete the e-Diary ( Section  7.1.1 ) for 
[ADDRESS_1049234] prior to the visit.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 52 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  6.3 Visit  2 Active Run -in Period   
All assessments  and procedures to be performed at Visit  2 are listed below.  
‚Ä¢ The subject will complete the questionnaire  (ISI), in the e-Diary (Section  [IP_ADDRESS].2 ), at the 
trial site before any consultation with the  trial site personnel  takes place.  
‚Ä¢ Inclusion and exclusion criteria will be evaluated.  
‚Ä¢ Body weight will be measured.  
‚Ä¢ Vital signs (blood pressure and heart rate) will be measured.  
‚Ä¢ The subject will be interviewed about any changes in concomitant medication and about any 
adverse events since the last visit.  
‚Ä¢ Blood samples w ill be drawn for assessment of c opeptin . 
‚Ä¢ The subject will be reminded about  lifestyle changes  (Section  4.3.3 ). 
‚Ä¢ Instructions for start and use of IMP will be given . 
‚Ä¢ IMP will be dispensed to eligible subjects  for the 1 -week active run -in (Table 5-1). 
Prior to Visit  [ADDRESS_1049235] will be reminded to complete the e -Diary (Section  7.1.1 ) for 
3 consecutive days prior to the visit.  The e -Diary will be reviewed for completeness (via the 
web-portal) by [CONTACT_765400] .  
Four days after  the planned start of IMP treatment  the subject will be telephone d to follow -up on 
safety .  
6.4 Visit  3 Washout Period  
All assessments  and proce dures to be performed at Visit  3 are listed below.  
‚Ä¢ Inclusion and exclusion criteria will be  evaluated  (specifically inclusion criterion  number  9, 
Section  4.1.1 ). 
‚Ä¢ Eligible subjects will enter the 1 -week Washout -period.   
‚Ä¢ The subject will be interviewed about any changes in concomitant medication and about any 
adverse events since the last visit.  
‚Ä¢ Body weight will be measured.  
‚Ä¢ Vital signs (blood pressure and heart rate) will be measured.  
‚Ä¢ A blood sample will be collected for analysis of serum sodium.  
‚Ä¢ Used IMP bottles,  ODT blister sheet s and unused IMP will be collected for drug 
accountability.  
‚Ä¢ The subject  will be reminded about  lifestyle changes  (Section  4.3.3 ). 
If the subject cannot attend Visit [ADDRESS_1049236] the serum sodium 
level at Day 6 -8 from the IMP start date.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 53 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049237] will be reminded to complete the e -Diary ( Section  7.1.1 ) for 
3 consecutive days prior to the visit.  The e -Diary will be reviewed for completeness (via the 
web-portal ) by [CONTACT_765400] .  
6.5 Visit  4 
All assessments/proce dures to be performed at Visit  4 are listed below.  
‚Ä¢ The subject will complete the questionnaires (ISI and Bother), in the e-Diary 
(Section  7.1.1 ), at the trial, site before any consultation with the  trial site personnel  takes 
place.  
‚Ä¢ Inclusion and exclusion criteria will be evaluated  (specifically inclusion criterion  
number  10, Section  4.1.1 ). 
‚Ä¢ The subject will be interviewed about any changes in concomitant medication and about any 
adverse events since the last visit.  
‚Ä¢ A ph ysical examination including body weight, will be performed . 
‚Ä¢ Vital signs (b lood pressure and heart rate ) will be measured.  
‚Ä¢ Blood samples will be drawn for analysis of haematology , clinical chemistry , coagulation 
factors  and c opeptin . 
‚Ä¢ Urine samples will be collected for urinalysis.  
‚Ä¢ Serum pregnancy test will be performed in all pre - and perimenopausal female subjects.  
‚Ä¢ Eligible subjects will be randomised to a treatment group ( placebo , [ADDRESS_1049238] interim analysis) . 
‚Ä¢ The subject will be reminded about lifestyle  changes  (Section  4.3.3 ) and to wait for a 
minimum of 2 hours after eating their evening meal before taking the IMP . 
‚Ä¢ IMP will be dispensed  (Table 5-1). 
Prior to Visit  [ADDRESS_1049239] will be reminded to complete the e -Diary (Section  7.1.1 ) for 
3 consecutive days prior to the visit.  The e -Diary will be reviewed for completeness (via the 
web-portal) by [CONTACT_765400] .  
6.6 Visit  5 to Visit  7 
All assessments/proce dures to be performed at Visits  5 to 7 are listed below.  
‚Ä¢ The subject will complete the questionnaires ( Bother [Visits 5, 6 and 7] and ISI [Visit  6 
and 7]), in the e -Diary (Section  7.1.1 ), at the trial site before any consultation with the trial 
site personnel  takes place.  
‚Ä¢ The subject will be interviewed about any changes in concomitant medication and about any 
adverse events since the last visit.  
‚Ä¢ Body weight will be measured.  
‚Ä¢ Vital signs (blood pressure a nd heart rate) will be measured.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 54 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Blood samples will be drawn for analysis of haematology, clinical chemistry (including 
serum sodium) and coagulation factors (Visit 6). 
‚Ä¢ Urine samples will be collected for urinalysis.  
‚Ä¢ Used IMP bottles,  blister sheet s and un used IMP will be collected for drug accountability.  
‚Ä¢ IMP will be dispensed.  
‚Ä¢ The subject will be reminded about  lifestyle changes  (Section  4.3.3 ) and to wait for a 
minimum of 2 hours after eating their evening meal before taking the IMP.  
Prior to the next visit (Visits 6, 7 and 8)  the subject will be reminded to complete the e -Diary 
(Section  7.1.1 ) for 3 consecutive days prior to the visit.  The e -Diary will be reviewed for 
completeness (via the web -portal) by [CONTACT_765400] . 
6.7 Visit  8 ‚Äì End-of-Trial Visit  
All assessments/proce dures to be performed at Visit 8 are listed below.  
‚Ä¢ The subject will complete the questionnaires (ISI and Bother), in the e -Diary  
(Section  7.1.1 ), at the trial, site before any consultation with the  trial site personnel  takes 
place.  
‚Ä¢ The subject will be interviewed about any changes in concomitant medication and about any 
adverse events since the last visit.  
‚Ä¢ Physical examination  including body weight  will be performed.  
‚Ä¢ 12-lead ECG will be measured.  
‚Ä¢ Vital signs (b lood pressure and heart  rate) will be measured.  
‚Ä¢ Blood samples will be drawn for analysis of haematology , clinical chemistry (including 
serum sodium ), coagulation factors and copeptin.  
‚Ä¢ Urine samples will be collected for urinalysis.  
‚Ä¢ Serum pregnancy test will be performed in all p re- and perimenopausal female subjects.  
‚Ä¢ Used IMP bottles, blister sheets and unused IMP will be collected for drug accountability.  
In addition to the above, a sample of  subjects (from trial sites in the [LOCATION_003]) who have completed the 
trial, will be invited to  participate in an exit interview  (Section  [IP_ADDRESS] ), by [CONTACT_756],  within 
14 days of attending  the end -of-trial visit (Visit  8) to record the subjects‚Äô perception of what 
constitutes a meaningful change in the NI Diary Total Score.  
6.[ADDRESS_1049240] has withdrawn his/her consent. The subject 
may also contact [CONTACT_765401] s for an unscheduled visit. The unscheduled visit 
may include additional collection of blood samples for safety reasons. The unscheduled visit may 
also include additional assessments deemed necessary by [CONTACT_765402], EC Gs, or other procedures which were missed at a previous visit. All unscheduled visits 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 55 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  should be described (including the reason for the visit) and documented in the medical/source 
record, and in the eCRF.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 56 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  7 TRIAL  ASSESSMENTS  
7.1 Assessments Related to Endpoints  
7.1.1 e-Diary  
Subjects will receive an e-Diary  for completion containing : a 3-day voiding diary  (Section  [IP_ADDRESS] ), 
the N I Diary and  PRO  questionnaires as described in Section  [IP_ADDRESS] . The followin g items are 
included in the e -Diary:  
‚Ä¢ Time of daily IMP administration  
‚Ä¢ 3-Day Voiding Diary  
‚Ä¢ Nocturia Impact (NI) Diary¬© 
‚Ä¢ PRO questionnaires  
o Patient Global Impression of Severity (PGI -S) 
o Patient Global Impression of Improvement (PGI -I) 
o Insomnia Severity Index (ISI) 
o Hsu 5-point Likert Bother Scale  
At Visit  1, the subjects will be trained to complete the e -Diary, which they will be encouraged to 
complete at home for 5 days (Figure 3-2).  
If the subject is not able to complete the e -Diary assessments, due to technical issues, prior to 
Visit 2 (only), it is permitted that the subject r epeats the e -Diary assessments.  
The e-Diary will be reviewed  for completeness  by [CONTACT_765400], via the web portal, 
throughout the trial . 
[IP_ADDRESS]  3-Day Voiding Diary  
A 3-day voiding diar y (included in the e -Diary , Section  7.1.1 ) will be used to collect information 
regarding: time of voiding epi[INVESTIGATOR_1841], urine volume, wit h or without urgency, with or without 
incontinence  and other related information, including time of going to bed and  time of awakening  
in the morning . The subjects will be asked to complete voiding diaries over [ADDRESS_1049241] prior to  scheduled visits , as outlined in  Table 7-1 and shown in Figure 3-2 and 
Figure 3-3. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 57 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 7-1 Timing of Voiding Diary Assessments  
Voiding Diary Assessment  3 Consecutive Days Prior to Visit(s)  
Time of Going to Bed with the Intenti on to S leep 2, 3, 4, 5, 6, 7, 8   
Time of Awakening  in the Morning  2, 3, 4, 5, 6, 7, 8  
Assessment of U rgency and Incontinence Epi[INVESTIGATOR_1841]  2 
Number and Timing of Nocturnal Voids  6, 7 
Number and Timing of Voids during 24 -hours  2, 3, 4, 5, 8 
Nocturnal Urine Volume  3* 
24-hour Urine Volume  2, 4, 5, 8 
* Includes collection of total urine volume within 30 minutes of rising (in the morning)  
 
Effort should be made to ensure that the subject fills out the voiding diary (in the e -Diary) on the 
same weekdays throughout the trial for consistency , e.g., if the first voiding d iary (in the e -Diary) is 
started on a Monday, the subsequent e-Diary should al so be started on a Monday  (Table 7-2). 
During the night (the sleep period) before the visit no measurements will be recorded.  
Table 7-2 Example of Voiding Diary Completion When Vis it Planned for Friday  
 Monday  
Day-4 Tuesday  
Day -3 Wednesday  
Day-2 Thursday  
Day-1 Friday  
Visit Day  Saturday  Sunday  
Morning   
X X X    
Afternoon/  
E vening   
X X Finish 
voiding 
diary  
(in e-Diary ) 
X    
Night  Start 
voiding 
diary 
(in e-Diary ) 
X X X     
During the screening peri od, each subject must complete the  3-day voiding diary to document the 
severity of nocturia and to confirm the eligibility for the active run -in period. The voiding diary 
should be completed over [ADDRESS_1049242] complete a 3 -day voiding diary to 
document treatment response  of ‚â•20% decrease in the nocturnal diuresis (mL/min) that was 
recorded at Visit  [ADDRESS_1049243] prior  to Visit  3.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 58 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049244] prior to Visit  4. 
After randomisation  (Visit  4) each subject has to complete four  3-day voiding diaries prior to the 
scheduled trial visits.   
Nocturnal voids are defined as the voids occurring from [ADDRESS_1049245] nocturnal void.  
The s ponsor will provide the subjects with cups for measuring the  urine volume.  
Prior to each visit the subjects will receive reminders to complete the e -Diary.  
[IP_ADDRESS]  Nocturia Impact Diary  
Nocturia has wide -ranging implications for patients‚Äô quality of life, mainly through persistent, 
repeated sleep interruptions. Valid patient self -reported assessments of disease burden and benefit 
of therapy are essential to evaluate the full clinical value of treatment for the patient.  
The NI Diary is a validated, nocturia -specific tool available in multiple languages  and consists of a 
12-item questionnaire with 11 core items (Q1 -Q11) and an ove rall QoL impact question (Q12) 
(Holm -Larsen, 2014 ). It is used in conjunction with a v oiding diary to capture patient reported 
consequences of nocturia and its treatment. It has a recall period of one night and day. Responses 
are scored from 0 to 4 (lowest to highest impact). For Question 12, response options range from 
0 (not at all) to  4 (a great deal). The NI Diary total scores are calculated by [CONTACT_10621] [ADDRESS_1049246] scores are standardised from 0 to 100 (lowest to 
highest impact).   
The NI Diary will be included in t he e-Diary (Section  7.1.1 ), which will be completed by [CONTACT_205504], for the [ADDRESS_1049247] prior to scheduled visit s as outlined in Figure 3-2 
and Figure 3-3. The NI D iary should be completed in the evening and before completing the PGI-S 
and PGI -I questionnaires . 
One objective of this trial is to further validate the NI Diary,  as well as to establish what constitutes 
a meaningful change in the NI Diary Total Score. Thus, the disease -specific NI Diary will be 
further tested and validated  in connection with this trial.  This will be done through pshychometric 
validation, as described in Section  [IP_ADDRESS] , and through exit interviews, as described in 
Section  [IP_ADDRESS] . 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 59 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  [IP_ADDRESS]  Patien t Reported Outcome s 
The PRO instrument s (questionnaires) that will be used in the trial  are listed below. They should be 
completed in the following order : 
‚Ä¢ At home in the evening  (after completion of the NI Diary) : 
o Patient Global Impression of Severity (PGI -S) 
o Patient Global Impression of Improvement (PGI -I) 
‚Ä¢ At the trial site: 
o Insomnia Severity Index (ISI)  
o Bother ( Hsu 5-point Likert Bother Scale)  
The two PRO questionnaires that will be completed at the trial site (ISI and Hsu 5 -point Likert 
Bother Scale) are recommended to be completed before any other assessments are performed, by 
[CONTACT_2181] a quiet place without influence from the trial personnel or accompanying family or 
friends. It is not permitted to help the subject cho ose an answer or interpret or rephrase questions 
which the subject do es not understand. The subjects should be informed that there are no right or 
wrong answers and that all of the subjects‚Äô responses will remain confidential.  
[IP_ADDRESS].1  Patient Global Impression of Severity and Patient Global Impression of Disease 
Improvement  
Patient Global Impression of Disease scales are commonly used measures of symptom severity, 
treatment response and the efficacy of treatments ( Yalcin,  2003). The P GI-I and PGI -S will be 
included in the trial to indicate change or stability in global health status for anchor -based analyses 
to identify thresholds for clinically important change s in, e.g., NI Diary scores  and number of 
nocturnal voids, as described in a separate Psychometric Analysis Plan (PAP) . Moreover, b oth 
scales will be analysed for treatment effect , as described in Section  9.7.[ADDRESS_1049248] the 
current condition, the revised and patient -tested versions of PGI -I and PGI -S will refer to ‚Äònight -
time voiding‚Äô, as compared to ‚ÄòLUTS‚Äô ( Viktrup, 2012 ). 
The PGI -S is a prospective measure that measures a patient‚Äô s current severity reported as ‚ÄúNone,‚Äù 
‚ÄúMild,‚Äù ‚ÄúModerate,‚Äù or ‚ÄúSevere‚Äù ( coded as 1 -4). Scores on this measure will provide a patient -rated 
summary of the severity of the patient‚Äôs nocturia  symptoms . 
The PGI -I is a retrospective measure. It will provide a p atient -rated summary of change in nocturia 
since the start of trial treatment , reported as ‚ÄúVery much better,‚Äù ‚ÄúMuch better,‚Äù ‚ÄúA little better,‚Äù 
‚ÄúNo change,‚Äù ‚ÄúA little worse,‚Äù ‚ÄúMuch worse,‚Äù or ‚ÄúVery much worse,‚Äù (coded as 1 -7). 
PGI-S followed by  [CONTACT_380440]-I will  be completed by [CONTACT_765403] , as outlined in  Figure 3-2 and Figure 3-3. 
[IP_ADDRESS].[ADDRESS_1049249] consequences for daytime performance and well -being. 
Nocturia patients often report excessive daytime  sleepi[INVESTIGATOR_008], with some experiencing more severe 
symptoms, including increased rates of mood disorders and decrease of physical health. Fatigue is a 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 60 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  commonly reported symptom by [CONTACT_765404] a great amount of interferences with daily 
life. Sleepin ess has also been linked to increased risks for accidents, such as falling asleep while 
driving or work -related accidents ( Asplund, 2005 ; Ancoli -Israel, 2011 ).  
Nocturia is characteris ed by [CONTACT_765405] . The first sleep period is of high importance due 
to that deepest stages of sleep (most restorative sleep) typi[INVESTIGATOR_765360] (e.g. , to void ) patients are not able 
to make up for this during the rest of the night ( Bliwise, 2015 ). FUSP will be a secondary endpoint 
in the trial.  
Sleep quality will be measure d through the ISI, which is an instrument to quantify the  subject's 
perception of his/her insomnia severity. The ISI targets the subjective symptoms and consequences 
of insomnia as well as the degree of concern or distress caused by [CONTACT_765391] ( Bastien, 2001 ). 
The ISI comp rises of four `sleep -related' items and three `wake -related' items assessing the severity 
of sleep -onset and sleep maintenance difficulties (both nocturnal and early morning awakenings), 
satisfaction with current sleep pattern, interference with daily func tioning, noticeability of 
impairment attributed to the sleep problem  and degree of distress or concern caused by [CONTACT_620792]. Each item is rated on a [ADDRESS_1049250] before 
active run -in period (Visit  2), at the  randomisation visit (Visit  4), after 4 weeks (Visit  6), after 
8 weeks (Visit  7) and at the last trial visit after 12 we eks of treatment (Visit  8) as illustrated in  
Figure 3-2 and Figure 3-3. Since the ISI has a two -week recall, a reminder to think back two weeks 
will appear on the screen upon start of completion , in order to improve on quality  of the 
information captured . The ISI will be completed at Visit 2 in order to compare insomnia severity to 
other diseases presenting with insomnia, as recorded by [CONTACT_72244]. The ISI completed at the remaining 
visits (Visits  4, 6, 7 and  8) will be used to measure treatment effect.  
[IP_ADDRESS].[ADDRESS_1049251] on sleep, daily life, social life, 
mental health, fatigue, etc. ( Tikkinen, 2010 ). It has been shown that most nocturia patients are not 
very bothered by [CONTACT_765406], but that there is clearly a bot her threshold at two voids or more. 
Moreover, comparing two adjacent voiding categories at a time, the increase was statistically 
significant with each increment in number of nightly voids. To further assess the change in 
subjective bothersomeness of noctu ria, trial participants will be asked, ‚ÄúHow much has this 
frequency of night -time urination bothered you?‚Äù with response options including ‚Äúnot at all,‚Äù 
‚Äúslightly,‚Äù ‚Äúmoderately,‚Äù ‚Äúquite a bit,‚Äù and ‚Äúextremely.‚Äù This 5 -point Likert  scale has previously 
been used in a large epi[INVESTIGATOR_119262]  (Hsu, 2015). 
The Hsu 5-point Likert Bother Scale  will be completed by [CONTACT_765407] (Visit  4), after 1 week (Visit 5), after  4 weeks (Visit  6), after 8 weeks (Visit  7) and at 
the last trial visit after 1 2 weeks of treatment (Visit  8), as illustrated in Figure 3-2 and Figure 3-3. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 61 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  7.1.2 Adverse Events  
The procedures for collection and recording of adverse events are described in Section s 8 (Adverse 
Events)  and 8.5 (Serious A dverse Events).  
7.1.3 Clinical Laboratory Variables  
Urine and blood samples for assessment of safety laboratory values (urinalysis, haematology , 
coagulation factors  and clinical chemistry parameters including serum sodium) will be collected as 
presented in Table 6-1. A central laboratory will be used for the analyses (Section  7.3). Evaluation 
of the laboratory -based eligibility criteria will be determined by [CONTACT_765408]. The 
analytical parameters are listed in Table 7-3. 
Deta ils for handling of serum sodium samples are given in Section  [IP_ADDRESS] . 
Laboratory values will be reported to the investigator. Laboratory reports from the screening visit 
(Visit  1) must be available for evaluating the inclusion and exclusion criteria prior to t he active run -
in period (Visit  2) and before randomisation  (Visit  4). Measurements outside normal ranges will be 
assessed by [CONTACT_1694] ‚Äòabnormal, not clinically significant‚Äô or ‚Äòabnormal, clinically 
significant‚Äô. Any abnormal, clinically signific ant changes should be reported as adverse events  
(Section  8.2). The laboratory reports will be signed and dated by [CONTACT_093].  
Table 7-3 Safety Laboratory Variables  
Clinical Chemistry  Haematology  Coagulation  Urinalysis  
Alanine aminotransferase  Haemoglobin  von Willebrand  Factor  Blood  
Albumin  Haematocrit  Factor VIII  Glucose  
Albumin/Globulin ratio  Platelet count    Ketones  
Alkaline phosphatase  Red blood cell count   Urinary sediment 
(erythrocyte s, leukocytes)  Aspartate aminotransferase  White blood cell count with 
differential count 
(eosinophil s, monocyte s, 
basophil s, neutrophil s, 
lymphocyte s)  
Calcium   pH 
Chloride   Protein  
Creatinine   Urobilinogen  
Creatine phosphokinase    
Gamma -glutamyl 
transferase    Dipstick assessment and 
microscopic examination 
will be performed. A 
culture will be performed 
in case of abnormal values.  Glucose    
HbA 1c   
Potassium    
Sodium    
Total bilirubin    
Direct bilirubin    
Total protein    
Blood urea nitrogen    
Uric acid  
Triglycerides    
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 62 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  [IP_ADDRESS]  Serum Sodium  
Serum sodium levels will be monitored throughout the trial  as hyponatraemia is a potentially 
serious adverse drug reaction (ADR) associated  with desmopressin treatment  and may potentially 
be asso ciated with FE [ADDRESS_1049252] 
be rep orted as adverse events , as described in Section  8.2. 
Blood samples for analysis of serum sodium will be collected , preferably in the morning,  at 
Visits  1, 3, 5, 6, 7 and 8, as presented in Table 6-1. The risk for subjects developi[INVESTIGATOR_765361]  (serum monitoring plan) : 
Screening (Visit  1) 
All subjects must have normal serum sodium (‚â•13 5 mmol/L) at screening  (Visit 1). If the serum 
sodium value is <135  mmol/ L (re-tested  and confirmed , with results available within 7  days) the 
subject must be discontinued from the trial as a ‚Äòscreening failure‚Äô.  
Active Run -in Period  
During the 1 -week active run -in period, 4 days (¬±1 day) after the planned start of IMP treatment, 
the subject will be telephoned to follow -up on safety . 
Visit 3 
At Visit  3 (after the active run -in), if the serum sodium value is <130  mmol/L the investigator must 
immediately contact [CONTACT_765409]. If the serum sodium 
value is <130  mmol/L (re-tested  and confirmed , with results available within 7  days)  the sub ject 
will not be randomised to the  trial and must be discontinued from the trial as a ‚Äò screening failure‚Äô. 
The subject will be followed (by [CONTACT_093]) for safety until the serum sodium level is stable 
and not clinically significant, preferably until  at least ‚â•135  mmol/L.  
If the subject cannot attend Visit  [ADDRESS_1049253] is taking IMP . 
12-week Random ised Treatment Period  
During the 12  weeks randomised treatment period, any unexpected low serum sodium value  
(<135  mmol/L or a drop in serum sodium level >10 mmol/L) must be re -tested with at least 
2 additional consecutive tests to identify the nadir and d uration of the hyponatraemic epi[INVESTIGATOR_1865]. The 
serum sodium level should be re -tested within 5  (¬±2 days) since the previous test. The subject will 
be followed (by [CONTACT_093]) for safety until the serum sodium level is stable and not clinically 
significant , preferably until at least ‚â•135  mmol/L.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 63 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Any Time Point during the Trial  
If the serum sodium value is ‚â§125  mmol/L at any time point during the trial, the treatment with the 
IMP must be stopped immediately and the subject must be withdrawn from the trial.  All cases  of 
serum sodium values ‚â§125  mmol/L will be reported a s Serious Adverse Event  (SAEs ) 
(Section  8.5). The subject will be followed (by [CONTACT_093]) for safety until the serum sodium 
level is stable and not clinically significant, preferably until at least ‚â•135  mmol/L.  
Acute Intercurrent Illness  
In case of acute intercurrent illnesses characterised by [CONTACT_765410]/or electrolyte imbalance (s uch as 
systemic infections, fever, gastroenteritis), the treatment with IMP should be interrupted until the 
subject has fully recovered. The treatment can be re -started at the discretion of the investigator once 
the condition of the subject is stabilised.  
In addition, subjects may be called in for additional unscheduled visits due to safety reason, as 
described in Section  6.8. 
Additional Serum Sodiu m Testing  
Events that will trigger additional serum sodium testing include, but are not limited to, the 
following:  
‚Ä¢ If more than [ADDRESS_1049254] be re-tested, with results available 
prior to Visit  2. 
‚Ä¢ A subject is presenting with signs or symptoms of hyponatraemia  (e.g., headache, dizziness)  
‚Ä¢ A subject has gained more than 2 kilograms in body weight between visits (Section  7.2.4 ) 
‚Ä¢ If concomitant treatment with therapy that may induce hyponatraemia (Section  4.3.1 ) is 
initiated or dosing of an existing therapy is increased during the trial, additional serum 
sodium monitoring should be performed in the first week (4 -8 days) after initiation and 
again wi th follow -up as judged by [CONTACT_093], at least at 4 weeks . 
[IP_ADDRESS]  von Willebrand Factor and Factor VIII  
Blood samples for assessment of coagulation factors will be collected  at Visits  1, 4, 6 and 8 . 
The concentration s of the coagulation factors von Willebra nd Facto r (vWF) and Factor VIII (FVIII)  
were assessed in the phase  1 clinical trial , 000195 , after both oral and intravenous administration of 
FE 201836. The results indicated that  both v WF and F VIII were increased at high plasma 
concentration s of FE  201836. vWF started to increase at a plasma concentration of ap proximately 
150 pg/mL FE 201836  and FVIII at a plasma concentration of approximately 200  pg/mL . Such high 
plasma concentrations are unlikely to be reached in the urological doses proposed for t he present  
trial, however,  vWF and FVIII will be  measured as a safety precaution, and to  ensure  that these 
coagulation factors are not released in clinically significant amounts.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 64 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  [IP_ADDRESS]  Copeptin  
Blood samples for exploratory analysis of copeptin levels in plasma  will be collected at  Visit 2, 
Visit 4 and Visit  8. The biomarker copeptin  can be easily tested for , and is therefore used as an 
AVP surrogate to potentially identify low nocturnal vasopressin  levels in plasma . In patients with 
NP, an inverse circadian rhythm of vasopressin is suspected , resulting in low nocturnal 
concentrations, which may be the root cause of NP. Copeptin may be a useful biomarker to 
diagnose NP due to low levels of endogenous AVP , thereby [CONTACT_765411]  (Brunell,  2016) and consequently treatment with FE  201836.  
7.1.4 Vital Signs  
Diastolic and systolic blood pressure (mm  Hg) and heart rate (beats per minute) will be measured 
after resting for 5 minutes in a sitting position , according to usual clinical practice at all trial visits . 
Measurements outside normal ranges will be assessed by [CONTACT_1694] ‚Äòabnormal, not 
clinically significant‚Äô or ‚Äòabnormal, clinically signific ant‚Äô. Any abnormal, clinically significant 
changes  should be reported as adverse events.  
7.1.5 24-Hour Urine Volume  and Nocturnal Urine Volume  
Data on 24 -hour urine volume, i.e., including NUV, will be obtained from the 3 -day voiding diary 
(Section  [IP_ADDRESS] ) completed prior to Visits  2, 4, 5 and 8. In addition, NUV data will be obtained 
from the 3 -day voiding diary completed prior to Visit  3 (Table 7-1). 
7.2 Other Assessments  
7.2.1 Demographics  
Demographic data , including date of birth and race , will be collected at screening  (Visit  1). 
7.2.2 Medical History  
Information on clinically significant  previous a nd concomitant illnesses, signs or findings from 
assessments and examinations during the screening, including surgical history, will be recorded as 
medical history at the screening  visit (Visit  1). 
7.2.[ADDRESS_1049255] at entry and during the trial. Prohibited medications/therapi[INVESTIGATOR_765362]  4.3.2 . 
7.2.4 Body Weight and Height  
Body weight and height will be measured to calculate the body mass index (BMI). The eCRF will 
be configured to automatically calculate the BMI . Height (without shoes) will be measured at 
screening  (Visit  1). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 65 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Body weight (without overcoat and shoes) will be measured at all visits . The same scale  should  
preferably be used on the subject during the course of the trial for consisten cy in readings.  
If the subject has gained more than [ADDRESS_1049256] be 
measured , as described in Section  [IP_ADDRESS] . 
7.2.5 Physical Examination  
Physical examinations will be performed at Visits 1, 4 and 8 by [CONTACT_1720] a delegated 
sub-investigator (MD, Medical Doctor; DO, Doctor of Osteopathic Medicine;  PA, Physician 
Assistant; NP, Nurse Practitioner)  and must not be delegated to any other trial site personnel. The 
same individual should preferably perform the physical examinations for a subject for consistency 
in evaluation.   
A complete physical examina tion will include , at a minimum, assessments of the cardiovascular, 
respi[INVESTIGATOR_696], gastrointestinal, urological and neurological systems . Any abnormal, clinically 
significant changes should be reported as adverse events.  
7.2.[ADDRESS_1049257]  will be  performed in all pre - and peri -menopausal female subjects at 
screening ( Visit 1), Visit  4 and at the end -of-trial visit (Visit  8). A urine pregnancy test will also be 
performed at screening (Visit  1). 
Female s ubjects of childbearing potential must have documentation of an acceptable  effective  
method  of contraception , as described in Section  4.3.4 . Amenorrhea of >[ADDRESS_1049258].  
7.2.7 Electrocardiogram  
A 12 -lead ECG will be performed by [CONTACT_765412] 
(Visit  1) and at the end -of-trial visit (Visit  8). The ECG should be taken after resting for  5 minutes. 
The ECG print -out should be reviewed, signed  and dated by [CONTACT_093].  Any abnormal, 
clinically  significant changes shoul d be reported as adverse events.  
7.3 Handling of Biological Samples  
A trial -specific laboratory manual will be provided to the participating sites, describing in detail 
how to handle, store and transport the biological samples in this trial. All biological sam ples will be 
analysed at central laboratories and will be destroyed after the results  are available . For all 
biological samples collected in the trial, analyses beyond those described in the protocol can only 
be performed after obtaining the required appro vals. The processes related to handling biological 
samples will be described in the informed consent docu ments and  data protection legislation 
including local legislation will be adhered to.  
In addition to the central laboratory, a local laboratory may be used for analysis of serum sodium if 
a quick turn -around time of the result is needed (Section  [IP_ADDRESS] ). 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 66 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049259] participating in a clinical trial. It 
includes:  
‚Ä¢ Any unfavourable and unintended sign, symptom or disease temporally associated with the 
use of the IMP, whether or not considered to be caused by [CONTACT_2203].  
‚Ä¢ Adverse events commonly observed and adverse events anticipated based on the 
pharmacological effect of the IMP.  
‚Ä¢ Any laboratory abnormality, vita l sign or finding from physical  examination  assessed as 
clinically significant by [CONTACT_941] i nvestigator  (note: pre-existing conditions diagnosed through 
assessments and examinations at the  screening visit or during the screening period are not 
adverse events, but are recorded as medical history ). 
‚Ä¢ Accidental injuries, reasons for any change in medication (drug  and/or dose), reasons for 
any medical, nursing or pharmacy consultation, or reasons for admission to hospi[INVESTIGATOR_226943].  
‚Ä¢ Overdoses and medication errors with and without clinical consequences.  
8.[ADDRESS_1049260] visit.  
The sources of adverse events cover : 
‚Ä¢ The subject‚Äôs response to questions about his/her health (a standard non -leading question 
such as ‚ÄúHow have you been feeling since your last visit?‚Äù is asked  at each visit).  
‚Ä¢ Symptoms spontaneously reported by [CONTACT_423].  
‚Ä¢ Investigations and examinations where the findings are assessed by [CONTACT_2205].  
‚Ä¢ Other information relating to the subject‚Äôs health becoming known to the investigator (e.g. , 
hospi[INVESTIGATOR_11956]).  
8.2.[ADDRESS_1049261]‚Äôs eCRF with information about:  
‚Ä¢ Adverse event  
‚Ä¢ Date and time of onset (time can be omitted, if applicable)  
‚Ä¢ Intensity  
‚Ä¢ Causal relationship to IMP  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 67 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Action taken to IMP  
‚Ä¢ Other action taken  
‚Ä¢ Date and time of outcome (time can be o mitted, if applicable)  
‚Ä¢ Outcome  
‚Ä¢ Seriousness.  
Each of the items in the Adverse Event Log is described in detail in the following sections.  
Adverse Event  
Adverse events should be recorded as diagnoses, if available. If not, separate signs and symptoms 
should be recorded. One diagnosis/symptom should be entered per record.  
If a subject suffers from the same adverse event more than once and the subject recovers in between 
the events, the adverse events should be re corded  separately. If an adverse event changes i n 
intensity, a worst -case approach should be used when re cording  the event, i.e. the highest intensity 
and the longest duration of the event.a 
Note the following: A procedure is not an adverse event; the reason for conducting the procedure is. 
Hospi[INVESTIGATOR_765363]; the reason for hospi[INVESTIGATOR_184996]. Death is not an adverse 
event, but the cause of death is (an exception is sudden death of unknown cause, which is an 
adverse event).  
Date and Time of Onset  
The date of onset is the date when t he first sign(s) or symptom(s) were first noted . If the adverse 
event is an abnormal clinically significant laboratory test  or outcome of an examination , the onset 
date is the date the sample was taken  or the examination was performed .  
Intensity  
The intensity of an adverse event must be classified using the following  3-point scale:  
Mild:  Awareness of signs or symptoms, but no disruption of usual activity.  
Moderate:  Event sufficient to affect usual activity (disturbing).  
Severe:  Inability to work or pe rform usual activiti es (unacceptable).  
                                              
a  Exception: if an adverse event with onset before the first IMP administration (i.e., a pre -treatment adverse 
event) worsens in intensity, this must be recorded as two separate events. The initial adverse event should be 
recorded with outcome ‚Äúnot recovered ‚Äù and the date and time of outcome is when the intensity changed. The 
second adverse event should be recorded with date and time of onset when the intensity changed.  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 68 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049262] be classified as one of the 
following:  
Reasonable possibility:  
There is evidence or argument to suggest a causal relationshi p between the IMP and the adverse 
event , i.e., it is an ADR . The ADR  may occur as part of the pharmacological action of the IMP or 
may be unpredictable in its occurrence.  
No reasonable possibility:  
There is no reasonable evidence or argument to suggest a c ausal relationship between the IMP and 
the adverse event.  
Action Taken to IMP  
The action taken to the IMP in response to an adverse event must be classified as one of the 
following:  
‚Ä¢ No change (medication schedule maintained or no action taken)  
‚Ä¢ Withdrawn  
‚Ä¢ Interrupted  
Other Action Taken  
Adverse events requiring therapy must be treated with recognised standards of medical care to 
protect the health and well -being of the subject. Appropriate resuscitation equipment and medicines 
must be available to ensure the best possible treatment of an emergency situation.  
If medication is administered to treat the adverse event, this medication should be entered in the 
Concomitant Medication Log . 
Date and Time of Outcome  
The date and time  the subject recovered or died.  
Outcome  
The outcome of an adverse event must be classified as one of the following:  
‚Ä¢ Recovered (fully recovered or the condition has returned to the level observed at initiation 
of trial treatment)  
‚Ä¢ Recovered with sequelae (resulted in persistent or significant disability/incapacity)  
‚Ä¢ Recover ing (the event is improving)  
‚Ä¢ Not recovered  
‚Ä¢ Fatal  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 69 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049263]  
associated with desmopressin treatment ( Section  [IP_ADDRESS] ) and may potentially be associated with  
FE [ADDRESS_1049264] be reported as adverse events , as described in Section  8.2. 
All cases of serum sodium values ‚â§125 mmol/L are considered important medical events and must 
be reported as SAEs , as described in Section  8.5.[ADDRESS_1049265] and Global 
Pharmacovigilance at Ferring Pharmaceuticals A/S must be informed. The pregnancy should be 
reported via the pregnancy Report Form included in the eCRF system. In case the eCRF cannot be 
accessed and hence the Pregnancy Report Form cannot be fill ed in within the eCRF system, a paper 
Pregnancy Report Form available in the investigator‚Äôs file should be used and sent to Ferring 
Global Pharmacovigilance. Contact [CONTACT_765413] 8.5.[ADDRESS_1049266] until the birth of the infant and 4 -6 weeks after the birth 
of the infant. In general, the follow -up will include the course; duration and the outcome of the 
pregna ncy as well as neonatal health.  
If a pregnancy results in an abnormal outcome (birth defect/congenital anomaly) this must be 
reported as a n SAE  to Global Pharmacovigilance at Ferr ing Pharmaceuticals  A/S. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 70 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  8.5 Serious Adverse Events  
8.5.1 Serious Adverse Event Definition  
Table 8-1 Serious Adverse Events during the Trial  
An event is defined a serious 
adverse event if it:  Guidance  
results in death  Any event resulting in a fatal outcome must be fully documented and reported, 
including deaths occurring within [ADDRESS_1049267] always be exercised and when in doubt the case should be 
considered serious (i.e., if case fulfils the criterion for a medically important event). 
Hospi[INVESTIGATOR_11956] s for administrative  or social purposes do not constitute an SAE. 
Hospi[INVESTIGATOR_2144]/or surgical operations planned before trial inclusion are not 
considered adverse events, if the illness or disease existed before the subject was 
enrolled in the tria l, provided that the condition did not deteriorate during the trial.  
results in persistent or 
significant 
disability/incapacity  Disability/incapacity means a substantial disruption of a person‚Äôs ability to conduct 
normal life functions. In doubt, the deci sion should be left to medical judgement by 
[CONTACT_093].  
is a congenital anomaly/birth 
defect  Congenital anomaly/birth defect observed in any offspring of the subject conceived 
during treatment with the IMP.  
is an important medical 
event  Important m edical events are events that may not be immediately life -threatening or 
result in death or hospi[INVESTIGATOR_73250]. 
Examples of imp ortan t medical events include adverse event s that suggest a 
significant hazard, contraindication or precaution, occurrence of malignancy or 
development of drug dependency or drug abuse. Medical and scientific judgement 
should be exercised in deciding whether ev ents qualify as medically important . 
Important medical events include any suspected transmission of an infectious agent 
via a medicinal product. Any organism virus or infectious particle (e.g.,  prion protein 
transmitting Transmissible Spongiform Encephalop athy), pathogenic or non -
pathogenic, is considered an infectious agent. A transmission of an infectious agent 
may be suspected from clinical symptoms or laboratory findings indicating an 
infection in a subject exposed to a medicinal product.  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 71 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049268] 
possible details within 3 calendar days  of his/her knowledge of the SAE.  
The SAE Report Form is included in the eCRF system and mus t be completed . In case the eCRF 
cannot be accessed and hence the SAE Report Form cannot be filled in within the eCRF system, a 
paper SAE Report Form available in the investigator‚Äôs file should be used and sent to Ferring 
Global Pharmacovigilance using the  contact [CONTACT_2212]:  
Global Pharmacovigilan ce, Ferring Pharmaceuticals A/S  
E-mail:  
Fax:  
eCRF information regarding  demographics, a dverse events, medical history and concomitant 
medication is mandatory  for initial  reports and for follow -up reports if any changes have been 
made since the initial report.  
Additional information relevant to the SAE such as hospi[INVESTIGATOR_1097], results from investigations, 
e.g. laboratory parameters (that are not already uploaded in the eCRF), invasive procedures, scans 
and x -rays and autopsy results can be faxed or scanned and e -mailed to Ferring Global 
Pharmacovigilance using the contact [CONTACT_2213]. In any case this information must 
be supplied by [CONTACT_765414] r equest from the sponsor . On any copi[INVESTIGATOR_2146], such details 
such as subject‚Äôs name, address and hospi[INVESTIGATOR_765364].  
The investigator will supply the sponsor  and the IEC/IRB/REB  with any additional requested 
information such as results of post -mortem examinations and hospi[INVESTIGATOR_1097].  
Expedited Reporting by [CONTACT_765415], unexpected and with a reasonable 
possible causality  to the IMP  (referred to as suspected unexpected serious adverse reactions 
[S[LOCATION_003]Rs]) as judged by [CONTACT_765416] (i.e., 
investigators, IECs/IRBs/REBs and regulatory authorities) within the stipulated timeline s. The 
expectedness is assessed by [CONTACT_765417] r‚Äôs Brochure  for 
FE 201836. Unblinded SAEs will be assessed using the current relevant reference safety 
information, which for FE 201836 is in the Investigator‚Äôs Brochure an d for desmopressin in the 
Decentralised Procedure NOCDURNA Summary of Product Characteristics . 
SAEs will be considered reportable regardless of whether or not the IMP was used in accordance 
with the provisions in the protocol  and the applicable reference safety information document . 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 72 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049269]‚Äôs last visit, the investigator must follow -up on any adverse event classified as 
serious or considered to have a reasonable possible causality to the IMP until it is resolved or unt il 
the medical condition of the subject is stable.  All such relevant follow -up information must be 
reported to the sponsor . If the event is a chronic condition , the investigator and the sponsor  may 
agree that further follow -up is not required.  
8.6.[ADDRESS_1049270]‚Äôs last visit  and he/she assesses the 
SAE to have a reasonable possible causality to the IMP , the case will have to be reported to  the 
sponsor  via the paper SAE Report Form , regardless how long after the end of the trial this takes 
place.  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 73 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  9 STATISTICAL METHODS  
The Global Biometrics Department at  Ferring Pharmaceuticals A/S will be responsible for data 
management, the Statistical Analysis P lan (SAP)  and the statistical analyses, production of tables, 
listings and figures. This section outlines the planned statistical analysis of the primary endpoint 
and the planned statistical analyse s for the secondary endpoints. All analyses and further 
description of the statistical methodology for primary as well as secondary endpoints will be 
detailed in the SAP . The SAP will be available before  the first  interim analysis.  
The analysis concerning the psychometric validation of the NI  Diary is p rovided  in a separate  PAP.  
9.1 Operating Characteristics  
The operating characteristics and associated power are estimated for different dose -response 
scenarios by [CONTACT_765418] l Simulator (FACTS) 
version  5.6. The five sigmoidal  dose-response profiles that were used to simulate trial data are 
illustrated in Figure 9-1. Further details on the dose -response model an d the associated primary 
analy sis are given in Section  9.7.2  and Appendix 2 . 
 
Figure 9-1 Dose -Response S cenarios  
 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 74 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  The longitudinal data profile used in the simulations is based on pooled data from desmopressin 
clinical trials FE  992026  CS40 and FE 992026  CS41 (planned treatment group ). The following 
estimates and assumptions were used : 
‚Ä¢ Dose -response standard deviation ùúé= 0.95 voids  
‚Ä¢ A between to total variance (œÉ2) ratio of 0.90 and a true underlying œÉ of 0.95  
‚Ä¢ Response fractions of 0.8142, 0.9328  and 0.9874 at  Weeks 1, 4 and 8, respectively , as 
compared to the averaged dose -response at Week 12  
‚Ä¢ Varian ce fractions of 0.8481, 0.8329 and 0.8900 at Weeks 1, 4 and 8, respectively, as 
compared to the averaged dose -respo nse at Week 12  
Further design specifications were:  
‚Ä¢ During the initial 17 weeks the recruitment rate will increase linearly from 0  to 8.2 subjects 
per week  
‚Ä¢ After [ADDRESS_1049271] been initiated, the recruitment rate is assumed to 
remain c onstant at 8.2  subjects per week  
‚Ä¢ Constant dropout rate of 15% during the randomised treatment period  
‚Ä¢ First interim analysis when 125 subjects are randomised , thereafter interim analyses every 
8 weeks  
‚Ä¢ Up to the first interim  analysis  the allocation ratio is 2:2:1  for placebo, 500 ¬µg FE 201836 
and desmopressin  
‚Ä¢ After the first interim analysis the allocation ratios are 2:7 :1, for placebo, 50 -500 ¬µg 
FE 201836  and desmopressin   
o Subjects randomised  to FE 201836 will be dynamically allotted to 
50 ¬µg FE 201836, 100  ¬µg FE 201836, 150  ¬µg FE  201836, 250  ¬µg FE 201836, 
350 ¬µg FE  201836 or  500 ¬µg FE 201836  using response -adaptive allocation as 
outlined in Section  9.11. 
‚Ä¢ Maximum of [ADDRESS_1049272] s and 
probabilities for futility and success are presented  in Table 9-1. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 75 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 9-1 Operati ng Characteristics  
Dose -Response 
Scenario  Maximum 
response 
(ùõº2) ED 50 
(ùõº3) Average 
Number of 
Subjects  Futility 
Stoppi[INVESTIGATOR_765349] 
(Total  
Success)  
Null 0 0 ¬µg 200 75.8% 97.0% 3.0% 
I -0.3 150 ¬µg  277 15.7% 47.9% 52.1% 
II -0.4 200 ¬µg  288 7.9% 25.1% 74.9% 
III -0.5 200 ¬µg  296 2.8% 9.6% 90.4% 
IV -0.5 350 ¬µg  295 3.4% 15.4% 84.6% 
V -0.6 300 ¬µg 298 1.4% 2.7% 97.3% 
 
For each dose -response scenario, 1 ,000 trials were simulated in order to estimate the operating 
characteristics presented in Table 9-1. The simulations under the null -hypothesis (no effect) 
demonstrate t hat assuming a maximum reduction versus placebo of 0.5 voids , the power 
(probability of success) reaches approximately 85 to 90%, while the probability of making a false 
positive conclusion is 3.0%. 
9.[ADDRESS_1049273] the conclusions of the  trial will be rated as major. Major 
protocol deviations will lead to exclusion of data from the Per Protocol (PP) analysis set  
(Section  9.3.5 ). Data up  to the point where the violation occurs wi ll be used in the evaluations.  
Major protocol deviations include, but are no t restricted to, the following:  
‚Ä¢ <2 nocturnal voids (average over 3 diaries) prior to Visit 2  or Visit  4 
‚Ä¢ NPi ‚â§33% prior to Visit  2 
‚Ä¢ <20% decrease in nocturnal diuresis rate (mL/min) from during active run -in (Visit  2 to 
Visit 3) 
‚Ä¢ Maximum voided volume <2 00 mL prior to Visit  2 
‚Ä¢ Actual treatment not in accordance with randomised  treatment  
‚Ä¢ Significant non -compliant treatment administration and e-Diary completion  
Serious unforeseen deviations deemed to impact the primary endpoint of the trial may additionally 
be rated as major protocol deviations by [CONTACT_765419] a blinded review of data befor e 
declaration of clean -file and lock of database. The list of major protocol deviations will be detailed 
and documented in the clean file document prior to database release  to the trial statistician . 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 76 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  9.3 Analysis Sets  
9.3.1 Intention -to-Treat  Analysis Set for the En richment (ITT -ENR)  Period  
The I ntention -to-Treat analysis set  for the e nrichment period  (ITT-ENR) will be comprised  of all  
subjects found to be eligible to enter the enrichment p eriod  (1 week active run -in and 1 week 
washout) at Visit  2. All analyse s will be conducted with respect to the planned treatment allocation.  
9.3.[ADDRESS_1049274] to actual treatm ent 
received . 
9.3.3 Intention -to-Treat (ITT) Analysis Set for the Randomised  Treatment Period  
The Intention -to-Treat (ITT) analysis set for the randomised treatment period will be comprised of 
all subjects randomised at Visit  4. All analyse s will be conducted with respect to the planned  
treatment allocation .  
9.3.4 Full Analysis Set (FAS)  
The Full Analysis Set (FAS)  will be comprised of all subjects in the ITT analysis set with at least 
one post -baseline record of  the number of nocturnal voids (pr imary endpoint). All analyses will be 
conducted with respect to the planned  treatment allocation.  
9.3.5 Per Protocol (PP) Analysis Set  
The PP analysis set will be  defined as all subjects included in the FAS except those for whom all 
data are excluded as a result  of major protocol deviations as described  in Section  9.2.  
9.3.[ADDRESS_1049275] one dose of IMP (placebo, FE  201836, or desmopressin) and have  had at lea st 
one safety assessment after r andomi sation (Visit  4). This also includes any subject  who wa s found 
not eligible at Visit  4, but who had at least one dose of IMP after Visit  4. All analysis will be 
conducted with respect to the actual treatment received . 
9.[ADDRESS_1049276] s screened, ITT -ENR and ITT analysis sets 
(Section  9.3.1  and 9.3.3 ) will be tabulated by [CONTACT_604793]. Reasons for not being 
randomised  at Visit  [ADDRESS_1049277] to the number of subjects in the safety analysis sets ( Section  9.3.2  and 
9.3.6 ), will be presented separate ly. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 77 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  1-Kaplan ‚ÄìMeier (1 -KM) plots  of time to early discontinuation per treatment group  will be 
displayed for the ITT analysis set and the treatment group difference will be tested using the 
Log-Rank test . In addition, time to early discontinuation by [CONTACT_765420]. All premature 
discontinuations will be s ummarised and listed by [CONTACT_765421], discontinuation.  
Presentations of subject d ispositions will be produced for the overall trial population and by [CONTACT_547].  
9.5 Enrichment P eriod  Assessments and Analysis Sets  
Descriptive statistics for demographics and other pre -baseline characteristics (e.g. , number of 
nocturnal voids, NPi, serum sodium levels, etc.) obtained at Visit  2 (latest) will be summarised for 
the ITT -ENR and the safety analysis set defined for the enrichment p eriod . Continuous  variables 
will be presented with number of subjects, mean, standard deviation, median, minimum and 
maximum. Categorical variables will be presented with number and percentage of subjects within 
each specific category.  
Treatment compliance, efficacy and s afety pertaining to the enrichment p eriod  (Visits 2 through 4) 
will be summarised by [CONTACT_765422] -ENR and Safety Analysis Set (as defined for the 
Enrichment p eriod ). Tables will be produced for the overall trial population and by [CONTACT_547]. 
Analyses of hyponatraemia  during the enrichment p eriod  are further described in Section  9.10.3 .  
9.6 Trial Population  
Descriptive statistics for  demographics and other baseline characteristics obtained at Visit  4 (latest)  
will be summaris ed for the ITT and safety analysis s et as outlined above. All data will be listed  per 
subject for the ITT analysis set. Gender specific tabulations will be provided.  
9.6.1 Medical Histor y, Concomitant Medication and Other Safety Evaluations  
Medical history will be coded using Medical Dictionary for Regulatory Activities  (MedDRA ). The 
version of MedDRA will be documented. Medical history will be listed by [CONTACT_765423] (SOC) and preferred term.  
Prior and concomitant medication will be summarised by [CONTACT_765424] m (ATC) classification first level (alphabetically), ATC classification second  
level (in decreasing order of frequency) and treatment group.  
9.[ADDRESS_1049278] deviation, median, 
inter-quartile range, minimum and maximum. Categorical variables will be presented with number 
and percentage of subjects within each spe cific category.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 78 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049279]. The posterior means estimates, 95% credib ility interval of the estimates  
and posterior probabilities of quantities of interest will be reported.  
Frequentist inferences will rely on the appropriate choice of model and report p-values 
corresponding to the statistical test of the hypothesis of ‚Äúequal effect‚Äù against the alternative of 
‚Äúdifferent effect‚Äù.  The level of significance is set at 5% (two -sided).   
Treatment comparison refers to the pair -wise comparison between active doses and placebo. There 
are no planned adjustments for multiplicity when pair -wise testing any active dose of FE  [ADDRESS_1049280].  
This section provides a brief background on the statistical Bayesian model that is utili sed.  
[IP_ADDRESS]  Statistical Dose -Response Model  
Let ùë•ùë°,ùëñ denote the observed cross -sectional change from baseline in nocturnal  voids (averaged 
across three consecutive nights) and let ùë¶ùë°,ùëñ denote the time -averaged change from baseline for 
subject  ùëñ up to time ùë°: 
ùë¶ùë°,ùëñ=‚àë ùë•ùëò,ùëñ ùë°
ùëò=1
ùë°, ùë°=1,2,3,4, 
where ùë° denotes the nominal post -baseline time -point reflecting data observed at Weeks 1, 4, 8 
and 12 (Visits  5, 6, 7 and  8, respectively). The final endpoint, ùë¶4,ùëñ, is modelled as being an 
observation of ùëå4,ùëñ~ùëÅ(ùúáùëë,ùëñ,ùúé2) where the dose -response at dose ùëë for subject ùëñ is adjusted for the 
number of baseline voids ( ùë•0,ùëñ) and assumed to follow a sigmoidal model:  
ùúáùëë,ùëñ=ùõΩùë•0,ùëñ+ùõº1+(ùõº2‚àíùõº1)ùëëùõº4
ùëëùõº4+ùõº3ùëé4=ùõΩùë•0,ùëñ+ùúáùëë, 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 79 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  and ùúé2 represents the (total error) variance of the dose -response . The interpretation of the 
parameters are: ùõº1 is the placebo response; ùõº2 is the maximum response; ùõº3 is the dose (ED 50) at 
which 50% of the maximum effect is obtained; ùõº4 is the slope parameter.  
The longitudinal aspect of the average change from baseline is captured by [CONTACT_430072] : 
ùëåùë°,ùëñ~ùëÅ(ùëíùõæùë°(ùúáùëë,ùëñ+ùõøùëñ),ùúÜùë°2), 
where the per -subject offset from the mean dose -response is ùõøùëñ~ùëÅ(0,ùúè2) and ùúÜùë°2 represents the 
within subject variance . The model is constrained such that ùõº4=0 and the intermediate values of ùë¶. 
can thus be thought of as being fractions of final value.  
Missing data (missing due to drop -out or final visit has not occurred yet) will be imputed using the 
longitudinal model, assuming missing at random. This implies that als o data from subjects who 
have not yet been observed at Week 12 are used in the primary efficacy analysis, as described in  
Appendix 2 . 
All parameters i n the models are given sufficiently non -informative prior distributions  as specified 
in Appendix 2 . By [CONTACT_765425]‚Äô theorem and Markov chain Monte Carlo sampling 
techniques the posterior probabilities (or the quantities of interest) given  in Table 9-[ADDRESS_1049281]  Probability Within  the Trial That: Objective  
Pr(ùúáùëÄùê¥ùëã <ùúáùëÉùëôùëè) the dose with the maximum effect (i.e. the dose 
that is most likely  to have the maximum effect) is 
superior to placebo  Proof -of-Concept  
Pr(ùúáùëÄùê¥ùëã ‚àíùúáùëÉùëôùëè<‚àí0.3) the dose with the maximum effect (i.e. the dose 
that is most likely  to have the maximum effect) has 
>0.3 voids reduction in nocturnal voids as 
compared to placebo  Futility  
Pr(dose d is MED)  dose d is the minimum dose that has >0.3 voids 
reduction in nocturnal voids as compared to 
placebo  Establish the 
MED  
Pr (dose  ùëë is ùê∏ùê∑ 85) dose d is the minimum dose that has > 85% of the 
treatment effect of the maximum effective dose  Establish ED 85 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 80 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  The final two quantit ies are also used to characteris e the dose -response curve (as they are calculated 
for each dose d) and to assign weights for the adaptive dose allocation.  
[IP_ADDRESS]  Overall Trial  Outcome  
The overall trial outcome will be presented in terms of the quantities of intere st in Table 9-3. 
Tabulated are also their criteria against which the overall trial success will be judged.  
Table 9-[ADDRESS_1049282] 
Interim  
Analysis  At Intermediate 
Interim Analyses  At the Final 
Analysis  
Futility  Pr(ùúáùëÄùê¥ùëã ‚àíùúáùëÉùëôùëè<‚àí0.3) <10%  <5%  
Success  Pr(ùúáùëÄùê¥ùëã <ùúáùëÉùëôùëè)   >97.5%  
 
[IP_ADDRESS]  Dose -Response  
The dose -response will be characterised by [CONTACT_765426] -response at 
each dose, ùúáùëë and the mean dose -response contrast versus placebo, their associated 95% credibility 
intervals and the posterior probability Pr(ùúáùëë<ùúáùëÉùëôùëè) will be tabulated. A ssociated with these, the 
following (posterior) probabilities  will also be tabulated:  Pr(ùúáùëë‚àíùúáùëÉùëôùëè<‚àí0.3), 
Pr(dose  ùëë is MED ), Pr (dose  ùëë is ùê∏ùê∑ 85) and Pr (dose d achieves  ùúáùëÄùê¥ùëã ).  
The mean dose -response will also be presented gr aphically with its 95% c redible interval.  
[IP_ADDRESS]  Sensitivity Analyse s 
The following sensitivity analyses will be conducted:  
‚Ä¢ The primary analys is will be carried out using the PP analysis sets.  
‚Ä¢ A completer analysis will be run testing the sensitivity of the imputation method applied in 
the primary analysis.  
‚Ä¢ The primary analys is using different priors specified in the SAP.  
‚Ä¢ Repeated measures Analysis of Covariance  (ANCOVA ) using a Missing Not At Random 
(MNAR) placebo -based pattern mixture model (Ratitch, 2011). 
[IP_ADDRESS]  Descriptive Analysis  
The raw average and raw average change from baseline at each dose will be tabulated together with 
95% confidence intervals. No imputations will be done for this analysis which will be based on the 
obser ved cases only.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 81 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  9.7.3 Secondary  and Explorative Analyses  
The following m ain categories of inferential analyse s will be performed for the secondary 
endpoints:  
‚Ä¢ Bayesian estimation of the Sigmoidal dose -response curve will follow the analysis 
described in  Section  [IP_ADDRESS] . Prior distributions for primary analysis  are specified in  
Appendix 2 , while prior distributions for secondary analyses will be specified in the SAP. 
The dose -response model for the 50% responder rates will also be further detailed in the 
SAP.  
‚Ä¢ Continuous treatment effect s at a certain visit will be analysed using SAS PROC MIXED 
assuming a repeated measures ANCOVA. (A non -parametric dose -response curve is 
assumed.) The changes from baseline per visit will be regressed upon the baseline 
observation as covariate  and treatment, vi sit and treatment -by-visit interaction as factors. An 
unstructured covariance structure will be used for the random subject effect. Least square 
mean estimates of the changes from baseline  and the treatment contrasts (with associated 
95% confidence interva ls) versus placebo will be tabulated and the changes from baseline 
will be graphically illustrated. Should only one post -baseline visit be obtained for an 
endpoint , an ANCOVA will be performed  without the visit and treatment -by-visit 
interaction terms . 
‚Ä¢ Correlation between endpoints will be reported using Pearson correlation coefficients and 
partial correlation where applicable.  
‚Ä¢ Binary endpoints such as ‚Äúresponder status ‚Äù at a certain visit will be analysed using SAS 
PROC GENMOD with the logit as link functi on for the responder probability. An 
unstructured covariance matrix will be assumed for the repeated responder status which will 
be adjusted for baseline value as covariate and treatment, visit and treatment -by-visit 
interaction as factors.  (Associated wit h e.g. , responder analysis in terms of reduction in 
number of voids, cumulative distritubtion function plots of percentage change from baseline 
by [CONTACT_765427].)  
Table 9-4 presents  the planned analys es. 
Illustration of the therapeutic window is described separately in Section [IP_ADDRESS]  and safety related 
endpoints are further described in Section  9.10. 
Explorati ve gender analyses are planned for all endpoints . For these the following are noted:  
‚Ä¢ Estimates of the gender specific dose -response during 12 weeks of treatment will follow the 
analysis described in  Section  [IP_ADDRESS]  by [CONTACT_765428]. 
Possible differences between the gender specific models will be investigated.  
‚Ä¢ Regression models will include gender and gender -by-treatment as  factors. (Possible 
differences between the treatment effects on gender will be evaluated by [CONTACT_765429] -by-treatment.)  
Correlation analyses will be done separately for each gender.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 82 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 9-4 Analysis of Endpoints  
Efficacy Endpoint  Analysis category  
Bayesian 
Estimation 
of Dose -
response 
Curve  Repeated 
measures 
ANCOVA  Correlation 
Analysis  Repeated 
logistic 
regression 
(Generalized 
Estimating 
Equation 
[GEE])  ANCOVA  
Change from baseline in number of nocturnal voids a Primary  Secondary e    
Responder rate defined as 50% reduction in nocturnal voids 
from baseline  a Secondary    Secondary   
Change from baseline in NI Diary Total Score  a Secondary  Secondary     
Percentage of nights during treatment period with at most one 
nocturnal void  i     Secondary  
Percentage of nights during treatment period with complete 
response  i     Secondary  
Change from baseline in NI Diary Overall Impact Score a Secondary  Secondary     
PGI-I urinary symptoms score  a,b  Secondary     
Change from baseline in PGI -S score a  Secondary     
Change from baseline in Bother as measured by [CONTACT_765376] 
5-point Likert Bother Scale  a  Secondary     
Change from baseline in ISI  f  Secondary     
Change from baseline in FUSP  a  Secondary  Secondary  Explorative  h   
Change from baseline in nocturnal diuresis rate (hourly)  c  Secondary     
Change from baseline in NUV c Secondary  Secondary     
Responder rates defined as 33%,  60%, 70%, 80%, 90% and 
100% reduction from baseline in number of nocturnal voids  a    Explorative   
Responder rates defined as 1, 2, and [ADDRESS_1049283]: Hyponatraemia Epi[INVESTIGATOR_765365]  9.10.3  
Clinic ally significant changes in vital signs and laboratory 
values  Sections 9.10.1  and 9.10.4  
a. Endpoint assessed at Weeks 1, 4, 8 and 12 weeks of  treatment.  
b. This questionnaire is retrospective and raw scores will be used in the 
analysis (not changes f rom baseline) and the ANCOVA model will 
not be adjusted f or baseline value.  
c. Endpoint assessed at Week 1 and 12 weeks of  treatment.  d. Endpoint assessed at 12 weeks of  treatment.  
e. Sensitivity analysis placebo pattern -mixture models.  
f. Endpoint assessed at Week 4, 8 and 12.  
g. Correlation with NPi [CONTACT_293778] 2.  
h. Correlation between changes in FUSP and total sleep time at Visits 
1, 4, 8 and 12.  
i. Endpoints are derived using all diary data collected during the 
treatment period . 
 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 83 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  [IP_ADDRESS]  Therapeutic Window  
The estimated dose -response curve (left -sided y -axis) will be illustrated together with the (3  month) 
incidences of serum sodium <130 mmol/L and ‚â§125 mmol/L (both on right -sided y -axis). The 
horizontal x -axis will represent the dose range of FE201836. The therapeutic window is defined as 
the dose range where FE  [ADDRESS_1049284] -case approach will be used: if causality is missing, the adverse eve nt 
will be regarded as related to the IMP; if the intensity of an adverse event is missing, the adverse  
event will be regarded as severe; if seriousness is missing the adverse event will be regarded as  
serious; if onset date is missing it will be assumed t o be the first day of dosing; if outcome is  
missing and no date of outcome is present the outcome is regarded as ‚Äòongoing ‚Äô. 
Data will be presented in summary tables and listings. Categorical data will be summarised by 
[CONTACT_765430] p ercentage of subjects in each category. For calculation of 
percentages, the denominator will be the total number of subjects in the respective treatment group 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 84 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049285] and treatment as observed including any  
derived values.  
9.10.2  Adverse Events  
Adverse events  will be summarised overall and tabulated by [CONTACT_2946] a nd preferred term using 
MedDRA. The version of MedDRA will be documented. The total number of subjects reporting an 
adverse event , the percentage of subjects (%) with an adverse event  and the number of events 
reported will be presented.  
Tables will be prep ared for the enrichment period  and randomised  treatment period  as outlined in 
Table 9-5. 
Table 9-5 Tabulations of Adverse E vents  
 E nrichment Period  
Enrichment 
period -emergent 
Adverse Event s 
(Safety Analysis Set 
Defined for the 
Enrichment Period ) Randomised  Period  
Treatment -emergent  
Adverse Events  
(Safety Analysis 
Data Set)  Gender -Specific 
Tabulations  
Overview of Adverse Events  X X Both  
Adverse Events  by [CONTACT_2235] (related/unrelated)  X X X 
Adverse Events  leading to death  X X Both  
Adverse Events  by [CONTACT_2236]   X X 
SAEs X X Both  
Adverse Events  leading to discontinuation  X X Both  
Adverse Events  with an incidence of at least 5% in 
any treatment group   X X 
Non-serious Adverse Events  with an incidence of 
at least 5% in any treatment group   X X 
 
9.10.[ADDRESS_1049286]: Hyponatraemia  Epi[INVESTIGATOR_765366]  (planned)  visit 
and treatment group. Similar tables wi ll be produced for both trial period s (enrichment and 
randomised) . 
The pre valence  of worst -case hyponatraemic epi[INVESTIGATOR_1841],  as defined in Table 9-6 will be presented by 
[CONTACT_765431].   
During the enrichment period (active run -in and washout) hyponatraemic epi[INVESTIGATOR_765367], but here the definition requires only one observatio n below the upper 
limit (‚â•135  mmol/L)  to yield a hyponatraemic epi[INVESTIGATOR_1865].   
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 85 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 9-6 Definition of Hyponatraemic Epi[INVESTIGATOR_765368]  
(mmol/L)  Number of Serum Sodium Observations  
‚â•135  Not applicable (normal serum sodium level)  
‚â•130 to <135  3 Consecutive Observations  a 
>125 to <130  2 Consecutive Observations  a 
‚â§125  1 Observation  
a Below upper threshold  
All subjects with a serum sodium value <130 mmol/L will be listed by [CONTACT_2948] , including 
all serum sodium assessments by [CONTACT_5586] -point and including respective demographic al data.  
Prese ntations will be done for the overall trial population and by [CONTACT_547].  
[IP_ADDRESS]  Hyponatr aemia during the Randomi sed Treatment Period  
These analyses are restricted to the Safety Analysis Set only.  
The incidence of the  post-baseline worst -case hyponataemia epi[INVESTIGATOR_765369] 9-6.  
Graphs will plot the serum sodium levels by [CONTACT_765432] s who at 
any time (Visit  1 and onwards) ha ve a serum sodium level <135 mmol/L will be highlighted.  
Kaplan -Meier plots of time from randomi sation (Visit  4) to hyponatraemic serum  sodium levels 
(<135, <130 and ‚â§ 125 mmol/L ) per treatment group will be produced. For the thresholds <135 and 
<130  mmol/L at least [ADDRESS_1049287] to be below the 
threshold to yield a hyponatraemic event (Table 9-6). For both cases the time is from randomisation 
until first observation bel ow the respective limit that counts.  
The associated relative hazards of treatment and gender will be analysed using Cox proportional 
hazards model adjusting  for baseline serum sodium and age (<65, ‚â•65  years ). Possible 
heterogeneity between the genders in the relative treatment hazards will be explored by [CONTACT_708870] a treatment -by-gender interaction term.  
9.10.[ADDRESS_1049288] results and their change from baseline to end -of-trial will be summarised by  
[CONTACT_765433] . The number and percent of subjects with clinically  
significant laboratory abnormalities will be presented. Shift tables f rom baseline to end -of-trial visit  
(categoris ed as low, normal  and high) will be presented by [CONTACT_1570].  
9.11 Interi m Analyses  
Two kind s of interim analyse s are planned in the trial. One is safety -oriented and concerns the 
monitoring of the serum sodium levels observed during the active run -in period . As described in 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 86 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  Section  3.4, a DMC will be established for the trial and make recommendations based on review of 
safety data , e.g., increase d rates of clinically significant serums sodium levels observed during the 
active run -in period , as described in Section  9.11.1 . The second kind concerns the pre -planned 
efficacy analyse s upon which the  trial may be stopp ed due to fu tility, or alloc ation probabilities  to 
FE201836 doses may be adjusted based on estimated dose -response curve , as described in 
Section  9.11.2 . 
9.11.1  Serum Sodium Monitoring during the Active Run -In Period  
The risk of subjec ts developi[INVESTIGATOR_765344] a serum sodium monitoring 
plan (Section  [IP_ADDRESS] ), including a 1 -week active run -in period to identify subjects at increased risk 
for developi[INVESTIGATOR_765345]. If the incidence of serum sodium levels 
<130  mmol/L  is statistically significantly >10% during the active run -in, the DMC  (Section  3.4) 
will be notified and further action will be discussed, e.g., the DMC may recommend that the highest 
dose of FE  201836 ma y be replaced by a lower dose.  
The number of cases of serum sodium lev els <130  mmol/L resulting in an estimated rate that is 
statistically significantly >10% depends on the number of subjects who have completed the active 
run-in, examples are presented in Table 9-7. 
Table 9-7 Examples of Incidence Rates that are Statistically Significantly >10%  
Number of S ubjects who 
have C ompleted 1 -week 
Active -run in  Number of Cases 
Observed with Serum 
Sodium levels 
<130  mmol/L  E stimate of Incidence 
Rate  Lower Limit of 95% 
Confidence Interval  
10 4 40% 12.2%  
20 6 30% 11.9%  
50 10 20% 10.0%  
100 17 17% 10.2%  
200 30 15% 10.4%  
 
Thus, t he present trial has been designed with the option  to decrease the maximal dose of 
FE [ADDRESS_1049289] interim analysis 
(when the first 125 subjects are randomised) the remaining subjec ts will be randomised to the 
following treatment groups: placebo, desmopressin (25 ¬µg for females and 50 ¬µg for males) or 
350 ¬µg FE 201836. After the interim analysis subjects may be randomised to one of 7 treatment 
groups: placebo, 50  ¬µg FE 201836, 100  ¬µg FE 201836, 150  ¬µg FE 201836, 250  ¬µg FE 201836, 
350 ¬µg FE 201836, or desmopressin (25 ¬µg for females and 50 ¬µg for males).  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 87 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  The dose -response model will be fitted across all doses, i.e., 0 -500 ¬µg, but inference will be made 
only on the doses that remain op en to randomisation e.g., 0 -350 ¬µg. That is, the MED and ED 85 
doses and the inferences with regards to proof -of-concept and futility will be limited to the dose 
range (i.e., with a maximum dose of 350  ¬µg FE  201836).  
9.11.2  Interim Efficacy Analyses  
The planned interim analys es will be conducted by [CONTACT_701805]  (Section  3.4) according to a 
separate DMC  charte r, which will be established before the first interim analysis . The interim 
analyses will use unblinded efficacy data to infer whet her to stop early for futility or to continue the 
trial as planned .  
At the first interim analysis the trial may be stopped due to futility if there is a low probability (less 
than 10%) that [ADDRESS_1049290]  0.3 voids more efficacious than placebo:  
Pr(ùúáùëÄùê¥ùëã ‚àíùúáùëÉùëôùëè<‚àí0.3)<10% . 
Up to the first interim analysi s (conducted when [ADDRESS_1049291] been  randomised ) the allocation 
ratio is 2:2:1 for placebo, 500 ¬µg FE 201836  and desmopressin. Should the trial continue, the 
allocation ratios will be  changed to 2:7:1 , where all doses of FE  201836 ( 50-500 ¬µg ) are opene d for 
response -adaptive allocation. The randomisation probabilities for each dose of FE  201836 will be 
proportional to the average of I(dose is MED) and I(dose is ED 85), where I(target)  is the square root 
of the probability that ‚Äúdose is target‚Äù scaled by [CONTACT_765434].  
The remaining interim analyses are planned to occur every 8 weeks as depi[INVESTIGATOR_765370] (Figure 9-2).  
These interim analyses will re -iterate the (overall) futility criteria at the 5% threshold:  
Pr(ùúáùëÄùê¥ùëã ‚àíùúáùëÉùëôùëè<‚àí0.3)<5% (see Table 9-2 for interpretation).  
At the final analysis (when all subject s have had their 12 -week visit, or discontinued prior to this 
visit) Proof -of-Concept is established if Pr(ùúáùëÄùê¥ùëã <ùúáùëÉùëôùëè)>97.5%.  
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 88 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   
 
Figure 9-2 Interim  Analysis Decision Tree ( 2nd Interim  Analysis  and Onwards)  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 89 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  10 DATA HANDLING  
10.1 Source Data and Source Documents  
Source Data ‚Äì International Conference on Harmonisation ( ICH ) Definition  
Source data are defined as all information in original records and certified copi[INVESTIGATOR_95937], observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data ar e contained in source documents (original 
records or certified copi[INVESTIGATOR_014]).  
Source Documents - ICH Definition  
Source documents are defi ned as original documents, data  and records (e.g. , hospi[INVESTIGATOR_1097], 
clinical and office charts, labora tory notes, memoranda,  subject  diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_164372], microfiches, photographic negatives, microfilm 
or magnetic med ia, x-rays, subject files and records kept at the pharmacy, at the laboratories and at 
medico -technical departments involved in the clinical trial).  
Trial -specific Source Data Requirements  - The Sponsor  
No specific protocol data can be recorded directly in  the e -CRF without a prior written or electronic 
record.  The data entered in the eCRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The e -Diary data is part of a 
process where the subject uses the e -Diary to transmit data to the service provider‚Äôs database, hence 
the service provide r‚Äôs database is considered to be the source data. The  investigator may need to 
request previous medic al records or transfer records, current me dical records must also be 
available.   
For each subject e nrolled, the investigator must document  in the  subject‚Äôs medical record,  that the 
subject participate s in this trial and at least the following information  must be recorded : 
‚Ä¢ Documentation of signed a nd dated informed consent  
‚Ä¢ Subject‚Äôs name [CONTACT_18131]  
‚Ä¢ Confirmation of participation in the trial (trial identification, screening/randomisation 
[subject] number)  
‚Ä¢ Eligibility of participation in the trial (inclusion/exclusion)  
‚Ä¢ Relevant medical history  
‚Ä¢ Nocturia medical history or subject -reported nocturia symptoms  
‚Ä¢ Visit Dates  
‚Ä¢ Results of any examinations/tests and assessment performed  
‚Ä¢ Details of any concomitant medication/therapy  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 90 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Details of any adverse events/SAEs (including description and duration)  
‚Ä¢ Date IMP is dispensed  and returned  
‚Ä¢ Reason for discontinuation/withdrawal, if applicable  
‚Ä¢ Event of unblinding, including the reason for unblinding, if applicable  
The following documents collected during the trial should be stored and archived together with the 
subject‚Äôs hospi[INVESTIGATOR_307]/medical records or in the investigator file as agreed upon prior to the trial start:  
‚Ä¢ Laboratory print -outs from central laboratory (and local laboratory, if used) ‚Äì evaluated, 
signed and dated by [CONTACT_093]  
‚Ä¢ ECG print -outs/reports - evaluated, signed and dated by [CONTACT_093]  
‚Ä¢ Subject  dispensing logs of IMP  
‚Ä¢ Relevant records for collection of laboratory samples  
‚Ä¢ Evaluations of physical examinations  
‚Ä¢ Demographics  
10.[ADDRESS_1049292] Research 
Organisation (CRO) will be used for data capture. The system is validated and access at all levels to 
the system is granted/revoked following sponsor  and vendor procedures, in accordance with 
regulatory and system requirements.  
Trial data should be entered into the eCRF in a t imely manner preferably within [ADDRESS_1049293]  visit.  
The investigator will approve/authorise the eCRF entries for each subject with an electronic 
signature [CONTACT_765445] t to a handwritten signature.  
The eCRF system and the database will be hosted at . After the trial database is 
declared clean and released to the statistician, a final copy of the database will be stored at the 
sponsor . The investigator will also receive a copy of the trial site‚Äôs final and locked data (including 
audit trail, electronic signature [CONTACT_2264]) as write -protected PDF -files produced by  
. The PDF -files will be stored electronically and will be provided by  [CONTACT_765435].  
Entry errors occurring in the eCRF will be corrected electronically. Such corrections/modifications 
will be automatically tracked by [CONTACT_765436], t he name 
[CONTACT_765446] . 
10.3 Use of Patient Reported Outcome s 
The PRO questionnaires  to be used in the trial are described in Section  [IP_ADDRESS] . 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 91 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049294] , either at the trial  site 
(ISI, Bother) or at home just prior to the trial visit (PGI -I, PGI -S), as outlined in Figure 3-2 and 
Figure 3-3. For PROs completed at home, subjects will be reminded in due time.  The 3-day 
e-Diary, including the PROs will be reviewed for completeness (via the web -portal) by [CONTACT_765437] ( Section  6). 
In case of missing  ISI and Bother  assessments, the reason (s) should be recorded by [CONTACT_765438] , e.g., subject refusal, lack of time from subject or functional li mitation from 
subject to complete the questionnaire.  Handling of missing assessments and missing data will be 
detailed in the SAP.  
10.3.[ADDRESS_1049295]  Diary  
[IP_ADDRESS]  Psychometric V alidation  
In connection with this trial, the NI Diary will be further tested and validated  through anchor -based 
analyses  including the PRO questionnaires PGI -I and  PGI-S (Section  [IP_ADDRESS].1 ) and subjects ‚Äô 
perception o f change  in NI Diary Total Score as captured in exit interviews (Section  [IP_ADDRESS] ). 
Details of these analyses are  described in a  separate PAP . The  order of these three e-Diary 
assessments , all completed at home, should therefore be NI Diary first, PGI -S second and PGI -I 
last, as described in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Validation through Exit Interviews  
A sample of subjects (from trial sites in the US A) who have completed the trial will be invited to 
participate in a n exit interview within 14 days of attending the end -of-trial visit (Visit 8). Signed 
informed consent must have been obtained through the ICF for the trial, as appropriate, before 
participation in the exit interview.  
The exact size of the sample will depend on when saturation has been reached. The subjects 
included will be proportionate to t he clinical trial sample distribution with respect to demographic 
and clinical characteristics. The investigator at the trial site will be asked to complete a Case Report 
Form that includes specific requirements for recruiting subjects to ensure the correc t mix of 
subjects.  
The exit interview  is designed  to examine the impact of living with nocturia and to assess what a 
meaningful positive change would be from the subject‚Äôs perspective in terms of this impact . In the 
exit interviews, subject s‚Äô ratings and perceptions of changes will be collected using qualitative  and 
quantitative methods. These data will be used to aid in understanding what is, from a subject‚Äôs 
perspective , a meaningful change threshold for indicating positive improvement in the impact of 
nocturia on a  subject‚Äôs lif e, as measured by [CONTACT_765439].  
A detailed description of the exit interview is provided in the Exit Interview Protocol, en closed in  
Appendix 1 . 
All exit interviews will be conducted over the telephone by a trained interviewer from
. 

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 92 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  10.4 Data Management  
A data management plan will be prepared under the responsibility of the  Global Biometrics 
Department at  Ferring Pharmaceuticals A/S. The data management plan will be issued before data 
collection begins and will describe all f unctions, processes  and specifications for data collection, 
cleaning a nd validation.  
10.[ADDRESS_1049296], the investigator will provide the sponsor  with additional data relating to the trial, duly 
anonymised and protected in accordanc e with applicable requirements.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 93 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049297] and visit the investigator periodically to ensure adherence to the protocol, 
International Conference of Harmonisation -Good Clinical Practice (ICH -GCP), standard operating 
procedures and applicable regulatory requirement s, maintenance of trial -related source records, 
completeness, ac curacy and verifiability of eCRF entries compared to source data, verification of 
drug accountability and compliance to safety reporting instructions.  
The investigator will permit the monitor  direct access to all source data, including electronic 
medical records and/or documents in order to facilitate data verification. The investigator will co -
operate with the monitor to ensure that any discrepancies that may be identified are resolved. The 
investigator is expected to be able to meet the monitor during these visits.  
Risk based monitoring will be applied for this trial. The frequency of the on -site monitoring visits 
will be adapted depending on the risk level of the site and workload. Site ris k is based on multiple 
factors including, but not limited to, the quantity of data generated, quality of the source 
documents, unreported adverse events or SAEs and number of protocol deviations.  
The risk -based monitoring and adaptive monitoring strategy, source data verification process and 
definition of key variables to be monitored will be described in detail in the Monitoring Plan for the 
trial.  
11.2 Audit and Inspection  
The investigator will make all the trial -related source data and records available at a ny time to 
quality assurance auditor(s) mandated by [CONTACT_456] , or to domestic/foreign regulatory inspectors 
or representatives  from IECs/IRBs /REBs  who may audit/inspect the trial.  
The main purposes of an audit or inspection are to assess compliance with the trial protocol and the 
principles of ICH -GCP including the Declaration of Helsinki (World Medical Association 
Declaration of Helsinki, 2013 ) and all other relevant regu lations.  
The subjects must be informed by [CONTACT_765440]/IRBs /REBs  may wish to inspect their medical records. During audits/insp ections the 
auditors/inspectors may copy relevant parts of the medical records. No personal identification apart 
from the screening/randomisation number will appear on these copi[INVESTIGATOR_014].  
The investigator should notify the sponsor  without any delay of any inspec tion by a regulatory 
authority or IEC/IRB /REB . 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 94 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049298] Data  
The investigator will ensure that the confidentiality of the subjects‚Äô data will be preserved. In the 
eCRF or any other documents  submitted to the sponsor , the subjects will not  be identified by [CONTACT_111242], but by [CONTACT_2250], which consists of an assigned number in the trial. 
Documents that are not for submission to the sponsor , e.g. , the confidential subject identification 
code and the signed Informed Consent Docu ments, will be maintained by [CONTACT_765441].  
11.4 Centralised Statistical Monitoring  
Centralised statistical monitoring will be conducted on (but not limited to) the following key 
aspects of the trial:  
‚Ä¢ The incidence rate of hyponatr aemia throughout  the trial 
‚Ä¢ Key inclusion criteria (number of voids, voided volumes, NI  Diary and B other)  
‚Ä¢ The number of voids and  NI Diary data as collected in the e -Diary throughout the trial 
‚Ä¢ Monitoring at trial site level will focus on the accumulated trial site data and comparisons 
across trial sites will be performed  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 95 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049299] OF THE TRIAL  
12.1 Protocol Amendments  
Any change to this protocol will be documented in a protocol amendment, issued by  [CONTACT_765442].  
Amendments may be submitted for consideration to the approving IEC s/IRBs /REBs  and regulatory 
authorities, in accordance with local regulations. Changes to the protoco l to eliminate immediate 
hazard s to trial subjects may be implemented prior to IECs/IRBs /REBs  approval/favourable 
opi[INVESTIGATOR_1649].  
12.[ADDRESS_1049300] be kept in the Investigator‚Äôs File and in the 
Trial Master File.  
12.3 Premature Trial Termination  
Both the investigator (with regard to his/her participation) and the sponsor  reserve the right to 
terminate the trial at any time. Sh ould this become necessary, the procedures will be agreed upon 
after consultation between the two parties. In terminating the trial, the sponsor  and the investigator 
will ensure that adequate consideration is given to the protection of the best interests o f the 
subjects. Regulatory authorities and IECs/IRBs /REBs  will be informed . 
In addition, the sponsor  reserves the right to terminate the participation of individual trial sites. 
Conditions that may warrant termination include, but are not limited to, insuf ficient adherence to 
protocol requirements and failure to enter subjects at an acceptable rate.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 96 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049301] the confidentiality of this proprietary information belonging to the 
sponsor . 
13.3 Publications and Public Disclosure  
13.3.1  Publication Policy  
At the end of the trial,  one or more manuscripts for joint publication may be prepared in 
collaboration between the investigator(s) offered authorship and the sponsor . In a multi -site trial 
based on the collaboration of many sites, any publication of results must acknowledge all sites. 
Results from multi -site trials must be reported in entirety in a responsible and coherent manner and 
results from subsets should not be published in advance or without clear reference to the primary 
publication of the entire trial.  
Authorship is gra nted based on the International Committee of Medical Journal Editors ( ICMJE ) 
criteria (see current official version: http://www.icmje .org). The total number of authors is based on 
the guideline from the relevant journal or congress. In the event of any disagreement in the content 
of a publication, both the investigator‚Äôs and the sponsor ‚Äôs opi[INVESTIGATOR_764351].  
Any external C RO or laboratory involved in the conduct of this trial has no publication rights 
regarding this trial.  
If the investigator wishes to independently publish/present any results from the trial, the draft 
manuscript/presentati on must be submitted in writing to the sponsor  for comment s prior to 
submission. Comments will be given within [ADDRESS_1049302] the disclosure of the sponsor ‚Äôs intellectual property. If the matter considered for 
publication is deemed patentable by [CONTACT_456] , scientific publication will not be allowed until 
after a filed patent application is published. Under such conditions the publication will be modified 
or delayed at the investigator‚Äôs discretion, to allow sufficient time for the sponsor  to seek patent 
protection of the invention.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 97 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049303] adopted a trials -registr ation policy as a condition for publication. 
This policy requires that all clinical trials be registered in a public, clinical trials registry. Thus, it is 
the responsibility of the sponsor  to register the trial in an appropriate public registry, i.e.  
www. ClinicalTrials.gov ; a website  maintained by [CONTACT_1055] (NLM) at the 
U.S. National Institutes of Health (NIH ). The trial will also be made publicly available at the  
European Union  (EU) Clinical Trials Register  at www.clinicaltrialsregister.eu . Trial registration 
may occur in other registries  in accordance with local regulatory requirements. A summary  of the 
trial results is made publicly available in accordance with applicable regulatory requirements.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 98 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  14 ETHICAL AND R EGULATORY ASPECTS  
14.1 Independent Ethics Committee  / Institutional Review Board  / Research Ethics Board  
An IEC /IRB/REB  will review the protocol and any amendments and advertisements used for 
recruitmen t. The IEC/IRB /REB  will review the subject information shee t and the ICF, their updates 
(if any)  and any written materials given to the subjects. A list of all IECs/IRBs /REBs  to which the 
protocol has been submitted and the name [CONTACT_765447] r eport.  
14.[ADDRESS_1049304] visit (Visit  8) of the last subject undergoing the 
trial. An end -of-trial declaration will be prepared when the tr ial has ended and will be submitted to 
the IEC s/IRB s/REBs  and regulatory authorities . 
14.[ADDRESS_1049305] their origins in the 
Declaration of Helsinki (World Medical Association Declaration of Helsinki, 2013 ), in c ompliance 
with the approved protocol, ICH -GCP and applicable regulatory requirements.  
14.[ADDRESS_1049306] Information and Consent  
The investigator (or the person  delegated by [CONTACT_093]) will obtain a freely given written 
consent from each subject after an appropriate explanation of the aims, methods, sources of 
funding, any possible conflicts of interest, anticipated benefits, potential risks of the trial and the 
discomfort it may entail, post -trial provisions and any other aspects of the trial which are relevant to 
the subject‚Äôs decision to participate. The trial subject must be given ample time to consider 
participation in the trial, before the consent is obtained. The Informed Consent Documents must be 
signed and dated by [CONTACT_765443] -related procedure, including screening 
tests fo r eligibility. Subjects must be given the option of being informed about the general outcome 
and the results of the trial.  
The investigator (or the person delegated by [CONTACT_093]) will explain that the subject is 
completely free to refuse to enter th e trial or to withdraw from it at any time, without any 
consequences for his/her further care and without the need to justify his/her decision.  
The subject will receive a copy of the subject i nformation and his/her signed ICF. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 99 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049307]‚Äôs willingness to 
continue par ticipation in the trial, a new subject i nformation and ICF will be forwarded to the 
IECs/IRBs /REBs  (and regulatory authorities, if required). The trial subjects will be informed  about 
this new information and re -consent will be obtained.  
Each subject will be informed that the monitor(s), quality assurance auditor(s) mandated by [CONTACT_103] , IRB/IEC /REB  representatives or regulatory authority inspector(s), in accordance with 
applicable regulatory requirements, may review his/her source records and data. Data protection 
will be handled in compliance with national/local regulations.  
14.[ADDRESS_1049308] bearing the following information:  
‚Ä¢ That he/she is participating in a clinical trial  
‚Ä¢ That he/she is treated with FE  201836  / Desmopressin  / Placebo  
‚Ä¢ The name [CONTACT_2266]  
‚Ä¢ The name, address and phone number of  the sponsor  
The subject will be asked  to keep the Subject Participation Card in their possession at all times 
during the trial and to return it at the last trial visit, if applicable.  
Each subject‚Äôs primary care physician will be notified of their participation in the trial by [CONTACT_192682] r, if the subject agrees and if applicable.  
14.7 Compliance Reference Documents  
The Declaration of Helsi nki (World Medical Association Declaration of Helsinki, 2013 ), the 
consolidated ICH -GCP, the EU Clinical Trial s Directive  and other national laws in the countries  
where the trial takes place shall constitute the main reference guidelines for ethical and regulatory 
conduct.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 100 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049309] igators, 
for dispensing the IMP in accordance with the approved protocol or an appro ved amendment  and 
for its secure storage and safe handling throughout the trial.  
15.2 Liabilities and Insurance  
Ferring Pharmaceuticals A/S is, as sponsor, responsible for ensur ing appropriate general/product 
liability insurance and, as required in accordance with applicable laws and regulations, country -
specific liability insurance coverage for claims made by a trial subject for injury arising from the 
subject‚Äôs participation in  the trial . 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 101 of 155 
 
 
 
 FE 201836  Trial C ode: [ADDRESS_1049310] be notified  in advance . If the investigator retires 
and the documents can no longer be archived by [CONTACT_779] , the sponsor  can arrange having the 
Investigator File archived at an external archive.  
16.2 Trial Master File  
The sponsor  will archive the Trial Master File in accordance with ICH -GCP and applicable 
regulatory requirements.  
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 102 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  17 REFERENCES  
Abrams P, Feneley R, Torrens M. Urodynamics . [LOCATION_001]: Springer -Verlag Berlin 
Heidelberg;1983. Chapter 2; Patient assessment; p.6 -27. 
Abrams  P, Mattiasson A, Lose GR, Robertson GL . The role of desmopressin in the treatment of 
adult nocturia. BJU Int.  2002; 90(suppl 3):[ADDRESS_1049311] of nocturia on sleep. Sleep Med Rev. 2011 
Apr;15(2):91 -7. 
Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern 
Med. 1991 Feb;229(2):131 -4. 
Asplund R. Nocturia: consequences for sleep and daytime activiti es and associated risks. Eur Urol 
Suppl . 2005;3(6):24 -32. 
Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome 
measure for insomnia research. Sleep Med. 2001 Jul;2(4):297 -307. 
Bliwise DL , Dijk DJ, Juul KV. Nocturia is associated with loss of deep sleep independent ly from 
sleep apnea. Neurourol Urodyn.  2015;34: 392. 
Bosch JL, Weiss JP. The Prevalence and Causes of Nocturia. J Urol. 2010;184(2):[ADDRESS_1049312] JP, Everaert K. 
Copeptin in nocturics: A posthoc explorative analysis.  Eur Urol Suppl 2016;  15: e539. 
Chartier -Kastler E, Tubaro A. The measurement of nocturia and its impact on quality of sleep and 
quality of li fe in LUTS/BPH. Eur Urol Suppl . 2006; 5:3-11. 
Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder health diaries: an 
assessment of 3 -day vs 7 day entries. BJU Int . 2005;96:1049 -54. 
U.S. Department of Health and Human Services Food and Drug Administration  (FDA). Guidance 
for Industry, Patient -Reported Outcome Measures: Use in Medical Product Development to  
Support Labeling Claims [Internet] . 2009 [cited 2016 Nov 30]. Available from: 
http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf  
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al. Diagnosis and 
treatment of overactive bladder (non -neurogenic) in adults: AUA/SUFU guideline [Internet]. 2014 
[cited 2016 Nov 30]. Available from: https://www.auanet.org/common/pdf/e ducation/clinical -
guidance/Overactive -Bladder.pdf  
Holm -Larsen T, Klein B, Weiss J. Correlation between voiding/sleep diaries, and nocturia and 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 103 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  sleep quality of life questionnaires. J Urol . 2009;181 (suppl 4):[ADDRESS_1049313] diary: a self -reported impact measure to comple ment the voiding diary. Value  Health. 2014 
Sept;17(6):696 -706. 
Hsu A, Nakagawa S, Walter LC, Van Den Eeden  SK, Brown JS, Thom DH, et al. The Burden of 
Nocturia Among Middle -Aged and Older Women. Obstet Gynecol. 2015;125(1):[ADDRESS_1049314] JP. Low-dose desmopressin 
combined with serum sodium monitoring can preve nt clinically significant hyponatraemia in 
patients treated for nocturia. BJU Int. 2016 Nov 15. [Epub ahead of print]  
Lose G, Lalos O, Freeman RM, van Kerrebroeck P; Nocturia Study Group. Efficacy of 
desmopressin (Minirin) in the treatment of nocturia: a double -blind placebo -controlled study in 
wome n. Am J Obstet Gynecol. [ADDRESS_1049315] ;189(4):1106 -13. 
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on 
AUA guideline on the management of benign prostatic hyperplasia. J Urol.  2011 May;185(5): 1793 -
803.doi: 10.1016/j.juro.2011.01.074.  
Mattiasson A. Efficacy of desmopressin in the treatment of nocturia: a double -blind placebo -
controlled study  in men. BJU Int. 2002;89(9): 855-62. 
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin  ML, Molsen E, et al. Content validity --
establishing and reporting the evidence in newly developed patient -reported outcomes (PRO) 
instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force 
report: part 2 -assessing respondent  understanding. Value Health. 2011;14(8):978 -88. 
Ratitch B, O‚ÄôKelly M. Implementation of Pattern -Mixture Models Using Standard SAS/STAT 
Procedures. Proceedings of PharmaSUG 2011 (Pharmaceutical Industry SAS Users Group), SP04, 
Nashville.  
Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF et al. ISOQOL 
recommends minimum standards for patient -reported outcome measures used in patient -centered 
outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889 -905. 
Tikkinen KA,  Johnson TM 2nd, Tammela TL, Sintonen H, Haukka J, Huhtala H, et al. Nocturia 
frequency, bother, and quality of life: how often is too often? A population -based study in Finland. 
Eur Urol. 2010;57(3):488 -96. 
van Kerrebroeck P, Abrams P, Chaikin D, Donovan  J, Fonda D, Jackson S, et al. The 
standardisation of terminology in nocturia: report from the Standardisation Sub -committee of the 
International Continence Society. Neurourol Urodyn. 2002;21(2):179 -83. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 104 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  van Kerrebroeck P. Desmopressin in the Treatment of Nocturia: A Double -Blind, Placebo -
Controlled Study. Eur Urol. 2007;52(1): 221‚Äì229. 
Verbalis JG , Goldsmith SR, Greenberg A , Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, 
evaluation, and treatment of hyponatremia: expert panel recommendations. Am J  Med. [ADDRESS_1049316];126([ADDRESS_1049317] 1): 1-42. 
Viktrup L, Hayes RP, Wang P, Shen W. Construct validation of patient global impression of 
severity (PGI -S) and improvement (PGI -I) questionnaires in the treatment of men with lower 
urinary tract symptoms secondary to ben ign prostatic hyperplasia. BMC Urology. 2012;12(1):1 -8. 
Wein A, Lose GR, Fonda D. Nocturia in men, women and the elderly: a practical approach. BJU 
Int. 2002 Dec;90 (Suppl 3 ):28-31. 
Weiss JP, Blaivas JG, Blanker MH, Bliwise DL, Dmochowski RR, Drake M, et al. The New 
England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes 
of therapy. BJU Int. 2013 May;111(5):700 -16. 
World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research 
Involving Hum an Subjects. 64th WMA General Assembly, Fortaleza, Brazil, October 2013 . 
Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J 
Obstet Gynecol. 2003;189(1):[ADDRESS_1049318]  JP. Gender difference in efficacy and dose 
response in Japanese patients with nocturia treated with 4 different doses of desmopressin orally 
disintegrating tablet in a randomized, placebo -controlled trial. BJU Int. 2013 Mar;111(3):474 -84. 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 105 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  18 APPENDI CES  
Appendix 1  
 
Exit Interview Protocol  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 106 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 107 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 108 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 109 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 110 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 111 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 112 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 113 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 114 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 115 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 116 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 117 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 118 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 119 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 120 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 121 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 122 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 123 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 124 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 125 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 126 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 127 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 128 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 129 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 130 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 131 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 132 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 133 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 134 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 135 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 136 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 137 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 138 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 139 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL                                      

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 140 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL                                    
 
Appendix 2  
 
Statistical Design and Operating Characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 141 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 142 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 143 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 144 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 145 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 146 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 147 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 148 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 149 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 150 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 151 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 152 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 153 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 154 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL  

Date: 05 Jul 2018  
E-Study Protocol -[ZIP_CODE]; Ver. 5.0  
Supersedes: 4.0 
Page 155 of 155 
 
 
 
 FE 201836  Trial C ode: 000233  
Oral Solution   
Clinical Trial Protocol  
Ferring Pharmaceuticals  CONFIDE NTIAL   
